1
|
Naka S, Ooe K, Shirakami Y, Kurimoto K, Sakai T, Takahashi K, Toyoshima A, Wang Y, Haba H, Kato H, Tomiyama N, Watabe T. Production of [ 211At]NaAt solution under GMP compliance for investigator-initiated clinical trial. EJNMMI Radiopharm Chem 2024; 9:29. [PMID: 38619655 PMCID: PMC11018728 DOI: 10.1186/s41181-024-00257-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Accepted: 03/21/2024] [Indexed: 04/16/2024] Open
Abstract
BACKGROUND The alpha emitter astatine-211 (211At) is garnering attention as a novel targeted alpha therapy for patients with refractory thyroid cancer resistant to conventional therapy using beta emitter radioiodine (131I). Herein, we aimed to establish a robust method for the manufacturing and quality control of [211At]NaAt solution for intravenous administration under the good manufacturing practice guidelines for investigational products to conduct an investigator-initiated clinical trial. RESULTS 211At was separated and purified via dry distillation using irradiated Bi plates containing 211At obtained by the nuclear reaction of 209Bi(4He, 2n)211At. After purification, the 211At trapped in the cold trap was collected in a reaction vessel using 15 mL recovery solution (1% ascorbic acid and 2.3% sodium hydrogen carbonate). After stirring the 211At solution for 1 h inside a closed system, the reaction solution was passed through a sterile 0.22 μm filter placed in a Grade A controlled area and collected in a product vial to prepare the [211At]NaAt solution. According to the 3-lot tests, decay collected radioactivity and radiochemical yield of [211At]NaAt were 78.8 ± 6.0 MBq and 40 ± 3%, respectively. The radiochemical purity of [211At]At- obtained via ion-pair chromatography at the end of synthesis (EOS) was 97 ± 1%, and remained > 96% 6 h after EOS; it was detected at a retention time (RT) 3.2-3.3 min + RT of I-. LC-MS analysis indicated that this principal peak corresponded with an astatide ion (m/z = 210.988046). In gamma-ray spectrometry, the 211At-related peaks were identified (X-ray: 76.9, 79.3, 89.3, 89.8, and 92.3 keV; γ-ray: 569.7 and 687.0 keV), whereas the peak at 245.31 keV derived from 210At was not detected during the 22 h continuous measurement. The target material, Bi, was below the 9 ng/mL detection limit in all lots of the finished product. The pH of the [211At]NaAt solution was 7.9-8.6; the concentration of ascorbic acid was 9-10 mg/mL. Other quality control tests, including endotoxin and sterility tests, confirmed that the [211At]NaAt solution met all quality standards. CONCLUSIONS We successfully established a stable method of [211At]NaAt solution that can be administered to humans intravenously as an investigational product.
Collapse
Affiliation(s)
- Sadahiro Naka
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
- Department of Pharmacy, Osaka University Hospital, 2-15 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Kazuhiro Ooe
- Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Yoshifumi Shirakami
- Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Kenta Kurimoto
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
- Department of Pharmacy, Osaka University Hospital, 2-15 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Toshihiro Sakai
- Hanwa Intelligent Medical Center, Hanwa Daini Senboku Hospital, 3176 Fukaikitamachi, Naka- ku, Sakai, Osaka, 599-8271, Japan
| | - Kazuhiro Takahashi
- Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima, 960-1295, Japan
| | - Atsushi Toyoshima
- Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Yang Wang
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama, 351-0198, Japan
| | - Hiromitsu Haba
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako, Saitama, 351-0198, Japan
| | - Hiroki Kato
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
- Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Noriyuki Tomiyama
- Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka, 565-0871, Japan
- Department of Radiology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
| | - Tadashi Watabe
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
- Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka, 565-0871, Japan.
| |
Collapse
|
2
|
Kaizuka Y, Suzuki H, Watabe T, Ooe K, Toyoshima A, Takahashi K, Sawada K, Iimori T, Masuda Y, Uno T, Kannaka K, Uehara T. Neopentyl glycol-based radiohalogen-labeled amino acid derivatives for cancer radiotheranostics. EJNMMI Radiopharm Chem 2024; 9:17. [PMID: 38407647 PMCID: PMC10897087 DOI: 10.1186/s41181-024-00244-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2024] [Accepted: 02/13/2024] [Indexed: 02/27/2024] Open
Abstract
BACKGROUND L-type amino acid transporter 1 (LAT1) is overexpressed in various cancers; therefore, radiohalogen-labeled amino acid derivatives targeting LAT1 have emerged as promising candidates for cancer radiotheranostics. However, 211At-labeled amino acid derivatives exhibit instability against deastatination in vivo, making it challenging to use 211At for radiotherapy. In this study, radiohalogen-labeled amino acid derivatives with high dehalogenation stability were developed. RESULTS We designed and synthesized new radiohalogen-labeled amino acid derivatives ([211At]At-NpGT, [125I]I-NpGT, and [18F]F-NpGT) in which L-tyrosine was introduced into the neopentyl glycol (NpG) structure. The radiolabeled amino acid derivatives were recognized as substrates of LAT1 in the in vitro studies using C6 glioma cells. In a biodistribution study using C6 glioma-bearing mice, these agents exhibited high stability against in vivo dehalogenation and similar biodistributions. The similarity of [211At]At-NpGT and [18F]F-NpGT indicated that these pairs of radiolabeled compounds would be helpful in radiotheranostics. Moreover, [211At]At-NpGT exhibited a dose-dependent inhibitory effect on the growth of C6 glioma-bearing mice. CONCLUSIONS [211At]At-NpGT exhibited a dose-dependent inhibitory effect on the tumor growth of glioma-bearing mice, and its biodistribution was similar to that of other radiohalogen-labeled amino acid derivatives. These findings suggest that radiotheranostics using [18F]F-NpGT and [123/131I]I-NpGT for diagnostic applications and [211At]At-NpGT and [131I]I-NpGT for therapeutic applications are promising.
Collapse
Affiliation(s)
- Yuta Kaizuka
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8675, Japan
| | - Hiroyuki Suzuki
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8675, Japan.
| | - Tadashi Watabe
- Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
- Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka, 560-0043, Japan
| | - Kazuhiro Ooe
- Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka, 560-0043, Japan
| | - Atsushi Toyoshima
- Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka, 560-0043, Japan
| | - Kazuhiro Takahashi
- Advanced Clinical Research Center, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan
| | - Koichi Sawada
- Department of Radiology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan
| | - Takashi Iimori
- Department of Radiology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan
| | - Yoshitada Masuda
- Department of Radiology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan
| | - Takashi Uno
- Department of Radiology, Chiba University Hospital, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8677, Japan
- Diagnostic Radiology and Radiation Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8670, Japan
| | - Kento Kannaka
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8675, Japan
| | - Tomoya Uehara
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, 260-8675, Japan.
| |
Collapse
|
3
|
Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, Watabe T, Ooe K, Yin X, Haba H, Shirasaki K, Kikunaga H, Tsukada K, Toyoshima A, Cardinale J, Giesel FL, Fukase K. Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides. Int J Mol Sci 2024; 25:933. [PMID: 38256007 PMCID: PMC10815831 DOI: 10.3390/ijms25020933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Revised: 01/05/2024] [Accepted: 01/07/2024] [Indexed: 01/24/2024] Open
Abstract
Currently, targeted alpha therapy (TAT) is a new therapy involving the administration of a therapeutic drug that combines a substance of α-emitting nuclides that kill cancer cells and a drug that selectively accumulates in cancer cells. It is known to be effective against cancers that are difficult to treat with existing methods, such as cancer cells that are widely spread throughout the whole body, and there are high expectations for its early clinical implementation. The nuclides for TAT, including 149Tb, 211At, 212/213Bi, 212Pb (for 212Bi), 223Ra, 225Ac, 226/227Th, and 230U, are known. However, some nuclides encounter problems with labeling methods and lack sufficient preclinical and clinical data. We labeled the compounds targeting prostate specific membrane antigen (PSMA) with 211At and 225Ac. PSMA is a molecule that has attracted attention as a theranostic target for prostate cancer, and several targeted radioligands have already shown therapeutic effects in patients. The results showed that 211At, which has a much shorter half-life, is no less cytotoxic than 225Ac. In 211At labeling, our group has also developed an original method (Shirakami Reaction). We have succeeded in obtaining a highly purified labeled product in a short timeframe using this method.
Collapse
Affiliation(s)
- Kazuko Kaneda-Nakashima
- Laboratory of Radiation Biological Chemistry, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan
- MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan; (Y.S.); (Y.K.); (T.W.); (K.O.); (A.T.); (K.F.)
- Department of Science, Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
| | - Yoshifumi Shirakami
- MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan; (Y.S.); (Y.K.); (T.W.); (K.O.); (A.T.); (K.F.)
- Department of Science, Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
| | - Yuichiro Kadonaga
- MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan; (Y.S.); (Y.K.); (T.W.); (K.O.); (A.T.); (K.F.)
- Nuclear Medicine, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan
| | - Tadashi Watabe
- MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan; (Y.S.); (Y.K.); (T.W.); (K.O.); (A.T.); (K.F.)
- Nuclear Medicine, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan
| | - Kazuhiro Ooe
- MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan; (Y.S.); (Y.K.); (T.W.); (K.O.); (A.T.); (K.F.)
- Radioisotope Research Center, Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
| | - Xiaojie Yin
- Nishina Center for Accelerator-Based Science Nuclear Chemistry Group, RIKEN, Wako 351-0198, Japan; (X.Y.); (H.H.)
| | - Hiromitsu Haba
- Nishina Center for Accelerator-Based Science Nuclear Chemistry Group, RIKEN, Wako 351-0198, Japan; (X.Y.); (H.H.)
| | - Kenji Shirasaki
- Laboratory of Alpha-Ray Emitters, Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan;
| | - Hidetoshi Kikunaga
- Research Center for Electron Photon Science, Tohoku University, Sendai 982-0826, Japan;
| | - Kazuaki Tsukada
- Research Group of Heavy Element Nuclear Science, Advanced Science Research Center, Japan Atomic Energy Agency, Naka-gun 319-1195, Japan;
| | - Atsushi Toyoshima
- MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan; (Y.S.); (Y.K.); (T.W.); (K.O.); (A.T.); (K.F.)
- Department of Science, Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
| | - Jens Cardinale
- Nuclear Medicine Department, University Hospital Düsseldorf, 40225 Düsseldorf, Germany; (J.C.); (F.L.G.)
| | - Frederik L. Giesel
- Nuclear Medicine Department, University Hospital Düsseldorf, 40225 Düsseldorf, Germany; (J.C.); (F.L.G.)
| | - Koichi Fukase
- MS-CORE, FRC, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan; (Y.S.); (Y.K.); (T.W.); (K.O.); (A.T.); (K.F.)
- Department of Science, Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
- Natural Product Chemistry, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan
| |
Collapse
|
4
|
Yagishita A, Katsuragawa M, Takeda S, Shirakami Y, Ooe K, Toyoshima A, Takahashi T, Watabe T. Development and Utility of an Imaging System for Internal Dosimetry of Astatine-211 in Mice. Bioengineering (Basel) 2023; 11:25. [PMID: 38247903 DOI: 10.3390/bioengineering11010025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Revised: 12/21/2023] [Accepted: 12/21/2023] [Indexed: 01/23/2024] Open
Abstract
In targeted radionuclide therapy, determining the absorbed dose of the ligand distributed to the whole body is vital due to its direct influence on therapeutic and adverse effects. However, many targeted alpha therapy drugs present challenges for in vivo quantitative imaging. To address this issue, we developed a planar imaging system equipped with a cadmium telluride semiconductor detector that offers high energy resolution. This system also comprised a 3D-printed tungsten collimator optimized for high sensitivity to astatine-211, an alpha-emitting radionuclide, and adequate spatial resolution for mouse imaging. The imager revealed a spectrum with a distinct peak for X-rays from astatine-211 owing to the high energy resolution, clearly distinguishing these X-rays from the fluorescent X-rays of tungsten. High collimator efficiency (4.5 × 10-4) was achieved, with the maintenance of the spatial resolution required for discerning mouse tissues. Using this system, the activity of astatine-211 in thyroid cancer tumors with and without the expression of the sodium iodide symporter (K1-NIS/K1, respectively) was evaluated through in vivo imaging. The K1-NIS tumors had significantly higher astatine-211 activity (sign test, p = 0.031, n = 6) and significantly decreased post-treatment tumor volume (Student's t-test, p = 0.005, n = 6). The concurrent examination of intratumor drug distribution and treatment outcome could be performed with the same mice.
Collapse
Affiliation(s)
- Atsushi Yagishita
- Kavli Institute for the Physics and Mathematics of the Universe (Kavli IPMU, WPI), The University of Tokyo, 5-1-5, Kashiwanoha, Kashiwa 277-8583, Japan
| | - Miho Katsuragawa
- Kavli Institute for the Physics and Mathematics of the Universe (Kavli IPMU, WPI), The University of Tokyo, 5-1-5, Kashiwanoha, Kashiwa 277-8583, Japan
| | - Shin'ichiro Takeda
- Kavli Institute for the Physics and Mathematics of the Universe (Kavli IPMU, WPI), The University of Tokyo, 5-1-5, Kashiwanoha, Kashiwa 277-8583, Japan
| | - Yoshifumi Shirakami
- Institute for Radiation Sciences, Osaka University, 1-1, Yamadaoka, Suita, Osaka 565-0871, Japan
| | - Kazuhiro Ooe
- Institute for Radiation Sciences, Osaka University, 1-1, Yamadaoka, Suita, Osaka 565-0871, Japan
| | - Atsushi Toyoshima
- Institute for Radiation Sciences, Osaka University, 1-1, Yamadaoka, Suita, Osaka 565-0871, Japan
| | - Tadayuki Takahashi
- Kavli Institute for the Physics and Mathematics of the Universe (Kavli IPMU, WPI), The University of Tokyo, 5-1-5, Kashiwanoha, Kashiwa 277-8583, Japan
| | - Tadashi Watabe
- Institute for Radiation Sciences, Osaka University, 1-1, Yamadaoka, Suita, Osaka 565-0871, Japan
| |
Collapse
|
5
|
Watabe T, Kabayama K, Naka S, Yamamoto R, Kaneda K, Serada S, Ooe K, Toyoshima A, Wang Y, Haba H, Kurimoto K, Kobayashi T, Shimosegawa E, Tomiyama N, Fukase K, Naka T. Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with 89Zr or 211At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma. J Nucl Med 2023; 64:1949-1955. [PMID: 37827841 PMCID: PMC10690121 DOI: 10.2967/jnumed.123.266313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2023] [Revised: 09/06/2023] [Indexed: 10/14/2023] Open
Abstract
Glypican-1 (GPC1) is overexpressed in several solid cancers and is associated with tumor progression, whereas its expression is low in normal tissues. This study aimed to evaluate the potential of an anti-GPC1 monoclonal antibody (GPC1 mAb) labeled with 89Zr or 211At as a theranostic target in pancreatic ductal adenocarcinoma. Methods: GPC1 mAb clone 01a033 was labeled with 89Zr or 211At with a deferoxamine or decaborane linker, respectively. The internalization ability of GPC1 mAb was evaluated by fluorescence conjugation using a confocal microscope. PANC-1 xenograft mice (n = 6) were intravenously administered [89Zr]GPC1 mAb (0.91 ± 0.10 MBq), and PET/CT scanning was performed for 7 d. Uptake specificity was confirmed through a comparative study using GPC1-positive (BxPC-3) and GPC1-negative (BxPC-3 GPC1-knockout) xenografts (each n = 3) and a blocking study. DNA double-strand breaks were evaluated using the γH2AX antibody. The antitumor effect was evaluated by administering [211At]GPC1 mAb (∼100 kBq) to PANC-1 xenograft mice (n = 10). Results: GPC1 mAb clone 01a033 showed increased internalization ratios over time. One day after administration, a high accumulation of [89Zr]GPC1 mAb was observed in the PANC-1 xenograft (SUVmax, 3.85 ± 0.10), which gradually decreased until day 7 (SUVmax, 2.16 ± 0.30). The uptake in the BxPC-3 xenograft was significantly higher than in the BxPC-3 GPC1-knockout xenograft (SUVmax, 4.66 ± 0.40 and 2.36 ± 0.36, respectively; P = 0.05). The uptake was significantly inhibited in the blocking group compared with the nonblocking group (percentage injected dose per gram, 7.3 ± 1.3 and 12.4 ± 3.0, respectively; P = 0.05). DNA double-strand breaks were observed by adding 150 kBq of [211At]GPC1 and were significantly suppressed by the internalization inhibitor (dynasore), suggesting a substantial contribution of the internalization ability to the antitumor effect. Tumor growth suppression was observed in PANC-1 mice after the administration of [211At]GPC1 mAb. Internalization inhibitors (prochlorperazine) significantly inhibited the therapeutic effect of [211At]GPC1 mAb, suggesting an essential role in targeted α-therapy. Conclusion: [89Zr]GPC1 mAb PET showed high tumoral uptake in the early phase after administration, and targeted α-therapy using [211At]GPC1 mAb showed tumor growth suppression. GPC1 is a promising target for future applications for the precise diagnosis of pancreatic ductal adenocarcinoma and GPC1-targeted theranostics.
Collapse
Affiliation(s)
- Tadashi Watabe
- Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Suita, Japan;
- Institute for Radiation Sciences, Osaka University, Suita, Japan
| | - Kazuya Kabayama
- Institute for Radiation Sciences, Osaka University, Suita, Japan
- Department of Chemistry, Graduate School of Science, Osaka University, Toyonaka, Japan
- Forefront Research Center, Graduate School of Science, Osaka University, Toyonaka, Japan
| | - Sadahiro Naka
- Department of Pharmacy, Osaka University Hospital, Suita, Japan
| | - Ryuku Yamamoto
- Department of Chemistry, Graduate School of Science, Osaka University, Toyonaka, Japan
| | - Kazuko Kaneda
- Institute for Radiation Sciences, Osaka University, Suita, Japan
- Forefront Research Center, Graduate School of Science, Osaka University, Toyonaka, Japan
| | - Satoshi Serada
- Institute for Biomedical Sciences Molecular Pathophysiology, Iwate Medical University, Yahaba, Japan
| | - Kazuhiro Ooe
- Institute for Radiation Sciences, Osaka University, Suita, Japan
| | | | - Yang Wang
- Nishina Center for Accelerator-Based Science, RIKEN, Saitama, Japan
| | - Hiromitsu Haba
- Nishina Center for Accelerator-Based Science, RIKEN, Saitama, Japan
| | - Kenta Kurimoto
- Department of Pharmacy, Osaka University Hospital, Suita, Japan
| | - Takanori Kobayashi
- Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Suita, Japan
| | - Eku Shimosegawa
- Department of Molecular Imaging in Medicine, Graduate School of Medicine, Osaka University, Suita, Japan
| | - Noriyuki Tomiyama
- Institute for Radiation Sciences, Osaka University, Suita, Japan
- Department of Radiology, Graduate School of Medicine, Osaka University, Suita, Japan; and
| | - Koichi Fukase
- Institute for Radiation Sciences, Osaka University, Suita, Japan
- Department of Chemistry, Graduate School of Science, Osaka University, Toyonaka, Japan
- Forefront Research Center, Graduate School of Science, Osaka University, Toyonaka, Japan
| | - Tetsuji Naka
- Institute for Biomedical Sciences Molecular Pathophysiology, Iwate Medical University, Yahaba, Japan
- Division of Allergy and Rheumatology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Yahaba, Japan
| |
Collapse
|
6
|
Iizuka Y, Manabe Y, Ooe K, Toyoshima A, Yin X, Haba H, Kabayama K, Fukase K. Exploring a Nuclear-Selective Radioisotope Delivery System for Efficient Targeted Alpha Therapy. Int J Mol Sci 2023; 24:ijms24119593. [PMID: 37298546 DOI: 10.3390/ijms24119593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 05/15/2023] [Accepted: 05/30/2023] [Indexed: 06/12/2023] Open
Abstract
Targeted alpha therapy (TAT) has garnered significant interest as an innovative cancer therapy. Owing to their high energy and short range, achieving selective α-particle accumulation in target tumor cells is crucial for obtaining high potency without adverse effects. To meet this demand, we fabricated an innovative radiolabeled antibody, specifically designed to selectively deliver 211At (α-particle emitter) to the nuclei of cancer cells. The developed 211At-labeled antibody exhibited a superior effect compared to its conventional counterparts. This study paves the way for organelle-selective drug delivery.
Collapse
Affiliation(s)
- Yuki Iizuka
- Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
| | - Yoshiyuki Manabe
- Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Forefront Research Center, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
| | - Kazuhiro Ooe
- Radioisotope Research Center, Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita 565-0871, Osaka, Japan
| | - Atsushi Toyoshima
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
| | - Xiaojie Yin
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako 351-0198, Saitama, Japan
| | - Hiromitsu Haba
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako 351-0198, Saitama, Japan
| | - Kazuya Kabayama
- Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Forefront Research Center, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
| | - Koichi Fukase
- Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Forefront Research Center, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Center for Advanced Modalities and DDS, Osaka University, 1-1 Yamadaoka, Suita 565-0871, Osaka, Japan
| |
Collapse
|
7
|
Aso A, Nabetani H, Matsuura Y, Kadonaga Y, Shirakami Y, Watabe T, Yoshiya T, Mochizuki M, Ooe K, Kawakami A, Jinno N, Toyoshima A, Haba H, Wang Y, Cardinale J, Giesel FL, Shimoyama A, Kaneda-Nakashima K, Fukase K. Evaluation of Astatine-211-Labeled Fibroblast Activation Protein Inhibitor (FAPI): Comparison of Different Linkers with Polyethylene Glycol and Piperazine. Int J Mol Sci 2023; 24:ijms24108701. [PMID: 37240044 DOI: 10.3390/ijms24108701] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2023] [Revised: 04/25/2023] [Accepted: 05/11/2023] [Indexed: 05/28/2023] Open
Abstract
Fibroblast activation proteins (FAP) are overexpressed in the tumor stroma and have received attention as target molecules for radionuclide therapy. The FAP inhibitor (FAPI) is used as a probe to deliver nuclides to cancer tissues. In this study, we designed and synthesized four novel 211At-FAPI(s) possessing polyethylene glycol (PEG) linkers between the FAP-targeting and 211At-attaching moieties. 211At-FAPI(s) and piperazine (PIP) linker FAPI exhibited distinct FAP selectivity and uptake in FAPII-overexpressing HEK293 cells and the lung cancer cell line A549. The complexity of the PEG linker did not significantly affect selectivity. The efficiencies of both linkers were almost the same. Comparing the two nuclides, 211At was superior to 131I in tumor accumulation. In the mouse model, the antitumor effects of the PEG and PIP linkers were almost the same. Most of the currently synthesized FAPI(s) contain PIP linkers; however, in our study, we found that PEG linkers exhibit equivalent performance. If the PIP linker is inconvenient, a PEG linker is expected to be an alternative.
Collapse
Affiliation(s)
- Ayaka Aso
- Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
| | - Hinako Nabetani
- Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
| | - Yoshifumi Matsuura
- Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
| | - Yuichiro Kadonaga
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita 565-0871, Osaka, Japan
| | - Yoshifumi Shirakami
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
| | - Tadashi Watabe
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita 565-0871, Osaka, Japan
| | - Taku Yoshiya
- Peptide Institute, Inc., 7-2-9 Saito-asagi, Ibaraki 567-0085, Osaka, Japan
- Institute for Protein Research, Osaka University, 3-2 Yamadaoka, Suita 565-0871, Osaka, Japan
| | | | - Kazuhiro Ooe
- Radioisotope Research Center, Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita 565-0871, Osaka, Japan
| | - Atsuko Kawakami
- Research Center for Ultra-High Voltage Electron Microscopy, Osaka University, 7-1 Mihogaoka, Ibaraki 567-0047, Osaka, Japan
| | - Naoya Jinno
- R&D Division, Alpha Fusion Inc., 10-1 Mihogaoka, Ibaraki 567-0047, Osaka, Japan
| | - Atsushi Toyoshima
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
| | - Hiromitsu Haba
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako 351-0198, Saitama, Japan
| | - Yang Wang
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako 351-0198, Saitama, Japan
| | - Jens Cardinale
- Department of Nuclear Medicine, University Hospital Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany
| | - Frederik Lars Giesel
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Department of Nuclear Medicine, University Hospital Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany
| | - Atsushi Shimoyama
- Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
| | - Kazuko Kaneda-Nakashima
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
| | - Koichi Fukase
- Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
| |
Collapse
|
8
|
Watabe T, Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, Ooe K, Wang Y, Haba H, Toyoshima A, Cardinale J, Giesel FL, Tomiyama N, Fukase K. Targeted α-therapy using astatine ( 211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound. Eur J Nucl Med Mol Imaging 2023; 50:849-858. [PMID: 36344651 PMCID: PMC9852121 DOI: 10.1007/s00259-022-06016-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2022] [Accepted: 10/18/2022] [Indexed: 11/10/2022]
Abstract
PURPOSE Targeted α-therapy (TAT) for prostate-specific membrane antigen (PSMA) is a promising treatment for metastatic castration-resistant prostate cancer (CRPC). Astatine is an α-emitter (half-life=7.2 h) that can be produced by a 30-MeV cyclotron. This study evaluated the treatment effect of 211At-labeled PSMA compounds in mouse xenograft models. METHODS Tumor xenograft models were established by subcutaneous transplantation of human prostate cancer cells (LNCaP) in NOD/SCID mouse. [211At]PSMA1, [211At]PSMA5, or [211At]PSMA6 was administered to LNCaP xenograft mice to evaluate biodistribution at 3 and 24 h. The treatment effect was evaluated by administering [211At]PSMA1 (0.40 ± 0.07 MBq), [211At]PSMA5 (0.39 ± 0.03 MBq), or saline. Histopathological evaluation was performed for the at-risk organs at 3 and 6 weeks after administration. RESULTS [211At]PSMA5 resulted in higher tumor retention compared to [211At]PSMA1 and [211At]PSMA6 (30.6 ± 17.8, 12.4 ± 4.8, and 19.1 ± 4.5 %ID/g at 3 h versus 40.7 ± 2.6, 8.7 ± 3.5, and 18.1 ± 2.2%ID/g at 24 h, respectively), whereas kidney excretion was superior in [211At]PSMA1 compared to [211At]PSMA5 and [211At]PSMA6. An excellent treatment effect on tumor growth was observed after [211At]PSMA5 administration. [211At]PSMA1 also showed a substantial treatment effect; however, the tumor size was relatively larger compared to that with [211At]PSMA5. In the histopathological evaluation, regenerated tubules were detected in the kidneys at 3 and 6 weeks after the administration of [211At]PSMA5. CONCLUSION TAT using [211At]PSMA5 resulted in excellent tumor growth suppression with minimal side effects in the normal organs. [211At]PSMA5 should be considered a new possible TAT for metastatic CRPC, and translational prospective trials are warranted.
Collapse
Affiliation(s)
- Tadashi Watabe
- Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
- Institute for Radiation Sciences, Osaka University, Osaka, Japan.
| | - Kazuko Kaneda-Nakashima
- Institute for Radiation Sciences, Osaka University, Osaka, Japan
- Core for Medicine and Science Collaborative Research and Education, Project Research Center for Fundamental Sciences, Graduate School of Science, Osaka University, Osaka, Japan
| | | | - Yuichiro Kadonaga
- Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
- Institute for Radiation Sciences, Osaka University, Osaka, Japan
| | - Kazuhiro Ooe
- Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan
- Institute for Radiation Sciences, Osaka University, Osaka, Japan
| | - Yang Wang
- Nishina Center for Accelerator-Based Science, RIKEN, Tokyo, Japan
| | - Hiromitsu Haba
- Nishina Center for Accelerator-Based Science, RIKEN, Tokyo, Japan
| | | | - Jens Cardinale
- Department of Nuclear Medicine, Dusseldorf University, Düsseldorf, Germany
| | - Frederik L Giesel
- Institute for Radiation Sciences, Osaka University, Osaka, Japan
- Department of Nuclear Medicine, Dusseldorf University, Düsseldorf, Germany
| | - Noriyuki Tomiyama
- Institute for Radiation Sciences, Osaka University, Osaka, Japan
- Department of Radiology, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - Koichi Fukase
- Institute for Radiation Sciences, Osaka University, Osaka, Japan
- Department of Chemistry, Graduate School of Science, Osaka University, Osaka, Japan
| |
Collapse
|
9
|
Götz M, Yakushev A, Götz S, Di Nitto A, Düllmann CE, Asai M, Chiera NM, Kindler B, Krier J, Lommel B, Nagame Y, Sato TK, Suzuki H, Tomitsuka T, Tokoi K, Toyoshima A, Tsukada K. Corrigendum to: Application of a novel gas phase synthesis approach to carbonyl complexes of accelerator-produced 5d transition metals (Radiochim. Acta 2022; 110 (2): 75–86). RADIOCHIM ACTA 2023. [DOI: 10.1515/ract-2022-0121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- Michael Götz
- Department of Chemistry – TRIGA Site , Johannes Gutenberg University Mainz , 55128 Mainz , Germany
- GSI Helmholtz Centre for Heavy Ion Research , 64291 Darmstadt , Germany
- Helmholtz Institute Mainz , 55099 Mainz , Germany
| | | | - Stefan Götz
- Department of Chemistry – TRIGA Site , Johannes Gutenberg University Mainz , 55128 Mainz , Germany
- GSI Helmholtz Centre for Heavy Ion Research , 64291 Darmstadt , Germany
- Helmholtz Institute Mainz , 55099 Mainz , Germany
| | - Antonio Di Nitto
- Physics Department Ettore Pancini , University of Naples Federico II , 80126 Naples , Italy
| | - Christoph E. Düllmann
- Department of Chemistry – TRIGA Site , Johannes Gutenberg University Mainz , 55128 Mainz , Germany
- GSI Helmholtz Centre for Heavy Ion Research , 64291 Darmstadt , Germany
- Helmholtz Institute Mainz , 55099 Mainz , Germany
| | - Masato Asai
- Japan Atomic Energy Agency , Tokai-Mura , Ibaraki 319-1111 , Japan
| | - Nadine M. Chiera
- Japan Atomic Energy Agency , Tokai-Mura , Ibaraki 319-1111 , Japan
| | - Birgit Kindler
- GSI Helmholtz Centre for Heavy Ion Research , 64291 Darmstadt , Germany
| | - Jörg Krier
- GSI Helmholtz Centre for Heavy Ion Research , 64291 Darmstadt , Germany
| | - Bettina Lommel
- GSI Helmholtz Centre for Heavy Ion Research , 64291 Darmstadt , Germany
| | - Yuichiro Nagame
- Japan Atomic Energy Agency , Tokai-Mura , Ibaraki 319-1111 , Japan
| | - Tetsuya K. Sato
- Japan Atomic Energy Agency , Tokai-Mura , Ibaraki 319-1111 , Japan
| | - Hayato Suzuki
- Japan Atomic Energy Agency , Tokai-Mura , Ibaraki 319-1111 , Japan
- Ibaraki University , Mito , Ibaraki 310-8512 , Japan
| | | | - Katsuyuki Tokoi
- Japan Atomic Energy Agency , Tokai-Mura , Ibaraki 319-1111 , Japan
- Osaka University , Suita , Osaka 565-0871 , Japan
| | - Atsushi Toyoshima
- Japan Atomic Energy Agency , Tokai-Mura , Ibaraki 319-1111 , Japan
- Osaka University , Suita , Osaka 565-0871 , Japan
| | - Kazuaki Tsukada
- Japan Atomic Energy Agency , Tokai-Mura , Ibaraki 319-1111 , Japan
| |
Collapse
|
10
|
Yonekura Y, Toki H, Watabe T, Kaneda-Nakashima K, Shirakami Y, Ooe K, Toyoshima A, Nakajima H, Tomiyama N, Bando M. Mathematical Model for Evaluation of Tumor Response in Targeted Radionuclide Therapy with 211At Using Implanted Mouse Tumor. Int J Mol Sci 2022; 23:ijms232415966. [PMID: 36555608 PMCID: PMC9788218 DOI: 10.3390/ijms232415966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Revised: 11/28/2022] [Accepted: 12/06/2022] [Indexed: 12/23/2022] Open
Abstract
Recent introduction of alpha-emitting radionuclides in targeted radionuclide therapy has stimulated the development of new radiopharmaceuticals. Preclinical evaluation using an animal experiment with an implanted tumor model is frequently used to examine the efficiency of the treatment method and to predict the treatment response before clinical trials. Here, we propose a mathematical model for evaluation of the tumor response in an implanted tumor model and apply it to the data obtained from the previous experiment of 211At treatment in a thyroid cancer mouse model. The proposed model is based on the set of differential equations, describing the kinetics of radiopharmaceuticals, the tumor growth, and the treatment response. First, the tumor growth rate was estimated from the control data without injection of 211At. The kinetic behavior of the injected radionuclide was used to estimate the radiation dose profile to the target tumor, which can suppress the tumor growth in a dose-dependent manner. An additional two factors, including the time delay for the reduction of tumor volume and the impaired recovery of tumor regrowth after the treatment, were needed to simulate the temporal changes of tumor size after treatment. Finally, the parameters obtained from the simulated tumor growth curve were able to predict the tumor response in other experimental settings. The model can provide valuable information for planning the administration dose of radiopharmaceuticals in clinical trials, especially to determine the starting dose at which efficacy can be expected with a sufficient safety margin.
Collapse
Affiliation(s)
- Yoshiharu Yonekura
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
- Research Center for Nuclear Physics, Osaka University, Suita 565-0047, Japan
- Correspondence:
| | - Hiroshi Toki
- Research Center for Nuclear Physics, Osaka University, Suita 565-0047, Japan
- Health Care Division, Health and Counseling Center, Osaka University, Toyonaka 560-0043, Japan
| | - Tadashi Watabe
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Suita 565-0871, Japan
| | | | | | - Kazuhiro Ooe
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
| | - Atsushi Toyoshima
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
| | - Hiroo Nakajima
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
| | - Noriyuki Tomiyama
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
- Department of Radiology, Osaka University Graduate School of Medicine, Suita 565-0871, Japan
| | - Masako Bando
- Yukawa Institute for Theoretical Physics, Kyoto University, Kyoto 606-8502, Japan
| |
Collapse
|
11
|
Kaneda-Nakashima K, Shirakami Y, Watabe T, Ooe K, Yoshimura T, Toyoshima A, Wang Y, Haba H, Fukase K. Effect to Therapy of Sodium-Iodine Symporter Expression by Alpha-Ray Therapeutic Agent via Sodium/Iodine Symporter. Int J Mol Sci 2022; 23:ijms232415509. [PMID: 36555151 PMCID: PMC9779414 DOI: 10.3390/ijms232415509] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Revised: 10/29/2022] [Accepted: 12/02/2022] [Indexed: 12/13/2022] Open
Abstract
This study confirmed the effect of sodium/iodine symporter (NIS) expression on existing drugs by in vitro and in vivo tests using cultured cell lines. The tumor growth inhibitory effect of sodium astatide ([211At]NaAt) was evaluated by in vitro and in vivo tests using human thyroid cancer cells (K1, K1/NIS and K1/NIS-DOX). NIS expression in cancer cells was controlled using the Tet-On system. [131I]NaI was used as control existing drug. From the results of the in vitro studies, the mechanism of [211At]NaAt uptake into thyroid cancer cells is mediated by NIS, analogous to [131I]NaI, and the cellular uptake rate correlates with the expression level of NIS. [211At]NaAt's ability to inhibit colony formation was more than 10 times that of [131I]NaI per becquerel (Bq), and [211At]NaAt's DNA double-strand breaking (DSB) induction was more than ten times that of [131I]NaI per Bq, and [211At]NaAt was more than three times more cytotoxic than [131I]NaI (at 1000 kBq each). In vivo studies also showed that the tumor growth inhibitory effect of [211At]NaAt depended on NIS expression and was more than six times that of [131I]NaI per Bq.
Collapse
Affiliation(s)
- Kazuko Kaneda-Nakashima
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Osaka University Graduate School of Science, 1-1 Toyonaka, Osaka 560-0043, Japan
- Institute for Radiation Sciences, Osaka University, 2-4 Suita, Osaka 565-0871, Japan
- Correspondence: ; Tel.: +81-6-6850-8271
| | - Yoshifumi Shirakami
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Osaka University Graduate School of Science, 1-1 Toyonaka, Osaka 560-0043, Japan
- Institute for Radiation Sciences, Osaka University, 2-4 Suita, Osaka 565-0871, Japan
| | - Tadashi Watabe
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Osaka University Graduate School of Science, 1-1 Toyonaka, Osaka 560-0043, Japan
- Institute for Radiation Sciences, Osaka University, 2-4 Suita, Osaka 565-0871, Japan
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Suita, Osaka 565-0871, Japan
| | - Kazuhiro Ooe
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Osaka University Graduate School of Science, 1-1 Toyonaka, Osaka 560-0043, Japan
- Institute for Radiation Sciences, Osaka University, 2-4 Suita, Osaka 565-0871, Japan
| | - Takashi Yoshimura
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Osaka University Graduate School of Science, 1-1 Toyonaka, Osaka 560-0043, Japan
- Institute for Radiation Sciences, Osaka University, 2-4 Suita, Osaka 565-0871, Japan
| | - Atsushi Toyoshima
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Osaka University Graduate School of Science, 1-1 Toyonaka, Osaka 560-0043, Japan
- Institute for Radiation Sciences, Osaka University, 2-4 Suita, Osaka 565-0871, Japan
| | - Yang Wang
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa Wako, Saitama 351-0198, Japan
| | - Hiromitsu Haba
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa Wako, Saitama 351-0198, Japan
| | - Koichi Fukase
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Osaka University Graduate School of Science, 1-1 Toyonaka, Osaka 560-0043, Japan
- Institute for Radiation Sciences, Osaka University, 2-4 Suita, Osaka 565-0871, Japan
- Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Toyonaka, Osaka 560-0043, Japan
| |
Collapse
|
12
|
Huang X, Kaneda-Nakashima K, Kadonaga Y, Kabayama K, Shimoyama A, Ooe K, Kato H, Toyoshima A, Shinohara A, Haba H, Wang Y, Fukase K. Astatine-211-Labeled Gold Nanoparticles for Targeted Alpha-Particle Therapy via Intravenous Injection. Pharmaceutics 2022; 14:pharmaceutics14122705. [PMID: 36559199 PMCID: PMC9782038 DOI: 10.3390/pharmaceutics14122705] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Revised: 11/26/2022] [Accepted: 11/30/2022] [Indexed: 12/12/2022] Open
Abstract
Alpha-particle radiotherapy has gained considerable attention owing to its potent anti-cancer effect. 211At, with a relatively short half-life of 7.2 h, emits an alpha particle within a few cell diameters with high kinetic energy, which damages cancer cells with high biological effectiveness. In this study, we investigated the intravenous injection of 211At-labeled gold nanoparticles (AuNPs) for targeted alpha-particle therapy (TAT). Different kinds of surface-modified gold nanoparticles can be labeled with 211At in high radiochemical yield in 5 min, and no purification is necessary. The in vivo biodistribution results showed the accumulation of 5 nm 211At-AuNPs@mPEG at 2.25% injection dose per gram (% ID/g) in tumors within 3 h via the enhanced permeability and retention (EPR) effect. Additionally, we observed a long retention time in tumor tissues within 24 h. This is the first study to demonstrate the anti-tumor efficacy of 5 nm 211At-AuNPs@mPEG that can significantly suppress tumor growth in a pancreatic cancer model via intravenous administration. AuNPs are satisfactory carriers for 211At delivery, due to simple and efficient synthesis processes and high stability. The intravenous administration of 5 nm 211At-AuNPs@mPEG has a significant anti-tumor effect. This study provides a new framework for designing nanoparticles suitable for targeted alpha-particle therapy via intravenous injection.
Collapse
Affiliation(s)
- Xuhao Huang
- Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
| | - Kazuko Kaneda-Nakashima
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
| | - Yuichiro Kadonaga
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita 565-0871, Osaka, Japan
| | - Kazuya Kabayama
- Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
| | - Atsushi Shimoyama
- Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
| | - Kazuhiro Ooe
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
| | - Hiroki Kato
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita 565-0871, Osaka, Japan
| | - Atsushi Toyoshima
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
| | - Atsushi Shinohara
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Faculty of Health Science, Osaka Aoyama University, 2-11-1 Niina, Minoh 562-8580, Osaka, Japan
| | - Hiromitsu Haba
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako 351-0198, Saitama, Japan
| | - Yang Wang
- Nishina Center for Accelerator-Based Science, RIKEN, 2-1 Hirosawa, Wako 351-0198, Saitama, Japan
| | - Koichi Fukase
- Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka 560-0043, Osaka, Japan
- Correspondence: ; Tel.: +81-6-6850-5391
| |
Collapse
|
13
|
Aso A, Kaneda-Nakashima K, Nabetani H, Kadonaga Y, Shirakami Y, Watabe T, Yoshiya T, Mochizuki M, Koshino Y, Ooe K, Kawakami A, Jinno N, Toyoshima A, Haba H, Wang Y, Cardinale J, Giesel FL, Shimoyama A, Fukase K. Substrate Study for Dihydroxyboryl Astatine Substitution Reaction with Fibroblast Activation Protein Inhibitor (FAPI). CHEM LETT 2022. [DOI: 10.1246/cl.220391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Ayaka Aso
- Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan
| | - Kazuko Kaneda-Nakashima
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan
| | - Hinako Nabetani
- Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan
- TechnoPro, Inc., 6-10-1, Roppongi, Minato-ku, Tokyo, 106-6135, Japan
| | - Yuichiro Kadonaga
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
| | - Yoshifumi Shirakami
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan
| | - Tadashi Watabe
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
| | - Taku Yoshiya
- Peptide Institute, Inc., 7-2-9 Saito-asagi, Ibaraki, Osaka 567-0085, Japan
- Institute for Protein Research, Osaka University, 3-2 Yamadaoka, Suita, Osaka 565-0871, Japan
| | | | - Yuki Koshino
- Peptide Institute, Inc., 7-2-9 Saito-asagi, Ibaraki, Osaka 567-0085, Japan
| | - Kazuhiro Ooe
- Radioisotope Research Center, Institute for Radiation Sciences, Osaka University, 2-4 Yamadaoka, Suita, Osaka 565-0871, Japan
| | - Atsuko Kawakami
- Research Center for Ultra-High Voltage Electron Microscopy, Osaka University, 7-1, Mihogaoka, Ibaraki, Osaka 567-0047, Japan
| | - Naoya Jinno
- R&D Division, Alpha Fusion Inc., 10-1, Mihogaoka, Ibaraki, Osaka 567-0047, Japan
| | - Atsushi Toyoshima
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan
| | - Hiromitsu Haba
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako Saitama, 351-0198, Japan
| | - Yang Wang
- RIKEN Nishina Center for Accelerator-Based Science, 2-1 Hirosawa, Wako Saitama, 351-0198, Japan
| | - Jens Cardinale
- Department of Nuclear Medicine, University Hospital Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany
| | - Frederik L. Giesel
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan
- Department of Nuclear Medicine, University Hospital Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany
| | - Atsushi Shimoyama
- Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan
| | - Koichi Fukase
- Department of Chemistry, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan
- Core for Medicine and Science Collaborative Research and Education, Forefront Research Center, Graduate School of Science, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan
- Division of Science, Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan
| |
Collapse
|
14
|
Yakushev A, Lens L, Düllmann CE, Khuyagbaatar J, Jäger E, Krier J, Runke J, Albers HM, Asai M, Block M, Despotopulos J, Di Nitto A, Eberhardt K, Forsberg U, Golubev P, Götz M, Götz S, Haba H, Harkness-Brennan L, Herzberg RD, Heßberger FP, Hinde D, Hübner A, Judson D, Kindler B, Komori Y, Konki J, Kratz J, Kurz N, Laatiaoui M, Lahiri S, Lommel B, Maiti M, Mistry AK, Mokry C, Moody KJ, Nagame Y, Omtvedt JP, Papadakis P, Pershina V, Rudolph D, Samiento L, Sato T, Schädel M, Scharrer P, Schausten B, Shaughnessy DA, Steiner J, Thörle-Pospiech P, Toyoshima A, Trautmann N, Tsukada K, Uusitalo J, Voss KO, Ward A, Wegrzecki M, Wiehl N, Williams E, Yakusheva V. On the adsorption and reactivity of element 114, flerovium. Front Chem 2022; 10:976635. [PMID: 36092655 PMCID: PMC9453156 DOI: 10.3389/fchem.2022.976635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Accepted: 07/19/2022] [Indexed: 12/01/2022] Open
Abstract
Flerovium (Fl, element 114) is the heaviest element chemically studied so far. To date, its interaction with gold was investigated in two gas-solid chromatography experiments, which reported two different types of interaction, however, each based on the level of a few registered atoms only. Whereas noble-gas-like properties were suggested from the first experiment, the second one pointed at a volatile-metal-like character. Here, we present further experimental data on adsorption studies of Fl on silicon oxide and gold surfaces, accounting for the inhomogeneous nature of the surface, as it was used in the experiment and analyzed as part of the reported studies. We confirm that Fl is highly volatile and the least reactive member of group 14. Our experimental observations suggest that Fl exhibits lower reactivity towards Au than the volatile metal Hg, but higher reactivity than the noble gas Rn.
Collapse
Affiliation(s)
- A. Yakushev
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
- *Correspondence: A. Yakushev,
| | - L. Lens
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - Ch. E. Düllmann
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - J. Khuyagbaatar
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
| | - E. Jäger
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - J. Krier
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - J. Runke
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - H. M. Albers
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - M. Asai
- Japan Atomic Energy Agency, Tokai, Japan
| | - M. Block
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - J. Despotopulos
- Lawrence Livermore National Laboratory, Livermore, CA, United States
| | - A. Di Nitto
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - K. Eberhardt
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | | | | | - M. Götz
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - S. Götz
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | | | | | | | - F. P. Heßberger
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
| | - D. Hinde
- Australian National University, Canberra, ACT, Australia
| | - A. Hübner
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - D. Judson
- University of Liverpool, Liverpool, United Kingdom
| | - B. Kindler
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | | | - J. Konki
- University of Jyväskylä, Jyväskylä, Finland
| | - J.V. Kratz
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - N. Kurz
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - M. Laatiaoui
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - S. Lahiri
- Saha Institute of Nuclear Physics, Kolkata, India
| | - B. Lommel
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - M. Maiti
- Indian Institute of Technology Roorkee, Roorkee, India
| | - A. K. Mistry
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
| | - Ch. Mokry
- Helmholtz-Institut Mainz, Mainz, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - K. J. Moody
- Lawrence Livermore National Laboratory, Livermore, CA, United States
| | - Y. Nagame
- Japan Atomic Energy Agency, Tokai, Japan
| | | | - P. Papadakis
- University of Liverpool, Liverpool, United Kingdom
| | - V. Pershina
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | | | | | - T.K. Sato
- Japan Atomic Energy Agency, Tokai, Japan
| | - M. Schädel
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - P. Scharrer
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - B. Schausten
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - D. A. Shaughnessy
- Lawrence Livermore National Laboratory, Livermore, CA, United States
| | - J. Steiner
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - P. Thörle-Pospiech
- Helmholtz-Institut Mainz, Mainz, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | | | - N. Trautmann
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - K. Tsukada
- Japan Atomic Energy Agency, Tokai, Japan
| | | | - K.-O. Voss
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - A. Ward
- University of Liverpool, Liverpool, United Kingdom
| | - M. Wegrzecki
- Łukasiewicz Research Network—Institute of Electron Technology, Warsaw, Poland
| | - N. Wiehl
- Helmholtz-Institut Mainz, Mainz, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - E. Williams
- Australian National University, Canberra, ACT, Australia
| | - V. Yakusheva
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
| |
Collapse
|
15
|
Watabe T, Liu Y, Kaneda-Nakashima K, Sato T, Shirakami Y, Ooe K, Toyoshima A, Shimosegawa E, Wang Y, Haba H, Nakano T, Shinohara A, Hatazawa J. Comparison of the Therapeutic Effects of [ 211At]NaAt and [ 131I]NaI in an NIS-Expressing Thyroid Cancer Mouse Model. Int J Mol Sci 2022; 23:ijms23169434. [PMID: 36012698 PMCID: PMC9409053 DOI: 10.3390/ijms23169434] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Revised: 08/09/2022] [Accepted: 08/18/2022] [Indexed: 12/11/2022] Open
Abstract
Astatine (211At) is an alpha-emitter with a better treatment efficacy against differentiated thyroid cancer compared with iodine (131I), a conventional beta-emitter. However, its therapeutic comparison has not been fully evaluated. In this study, we compared the therapeutic effect between [211At]NaAt and [131I]NaI. In vitro analysis of a double-stranded DNA break (DSB) and colony formation assay were performed using K1-NIS cells. The therapeutic effect was compared using K1-NIS xenograft mice administered with [211At]NaAt (0.4 MBq (n = 7), 0.8 MBq (n = 9), and 1.2 MBq (n = 4)), and [131I]NaI (1 MBq (n = 4), 3 MBq (n = 4), and 8 MBq (n = 4)). The [211At]NaAt induced higher numbers of DSBs and had a more reduced colony formation than [131I]NaI. In K1-NIS mice, dose-dependent therapeutic effects were observed in both [211At]NaAt and [131I]NaI. In [211At]NaAt, a stronger tumour-growth suppression was observed, while tumour regrowth was not observed until 18, 25, and 46 days after injection of 0.4, 0.8, and 1.2 MBq of [211At]NaAt, respectively. While in [131I]NaI, this was observed within 12 days after injection (1, 3, and 8 MBq). The superior therapeutic effect of [211At]NaAt suggests the promising clinical applicability of targeted alpha therapy using [211At]NaAt in patients with differentiated thyroid cancer refractory to standard [131I]NaI treatment.
Collapse
Affiliation(s)
- Tadashi Watabe
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Suita 565-0871, Japan
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
- Correspondence: ; Tel.: +81-6-6879-3461
| | - Yuwei Liu
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Suita 565-0871, Japan
| | - Kazuko Kaneda-Nakashima
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
- Core for Medicine and Science Collaborative Research and Education, Project Research Center for Fundamental Sciences, Osaka University Graduate School of Science, Suita 565-0871, Japan
| | - Tatsuhiko Sato
- Nuclear Science and Engineering Center, Japan Atomic Energy Agency, Shirakata 2-4, Tokai 319-1195, Japan
- Research Center for Nuclear Physics, Osaka University, Suita 567-0047, Japan
| | | | - Kazuhiro Ooe
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Suita 565-0871, Japan
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
| | - Atsushi Toyoshima
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
| | - Eku Shimosegawa
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
- Department of Molecular Imaging in Medicine, Osaka University Graduate School of Medicine, Suita 565-0871, Japan
| | - Yang Wang
- Nishina Center for Accelerator-Based Science, RIKEN, Wako 351-0198, Japan
| | - Hiromitsu Haba
- Nishina Center for Accelerator-Based Science, RIKEN, Wako 351-0198, Japan
| | - Takashi Nakano
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
- Research Center for Nuclear Physics, Osaka University, Suita 567-0047, Japan
| | - Atsushi Shinohara
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
- Department of Chemistry, Graduate School of Science, Osaka University, Toyonaka 560-0043, Japan
| | - Jun Hatazawa
- Institute for Radiation Sciences, Osaka University, Suita 565-0871, Japan
- Research Center for Nuclear Physics, Osaka University, Suita 567-0047, Japan
| |
Collapse
|
16
|
Kaizuka Y, Suzuki H, Watabe T, Shirakami Y, Ooe K, Teramoto T, Toyoshima A, Uehara T. At-211-labeled L-tyrosine derivatives via neopentyl scaffold for targeted α-therapy. Nucl Med Biol 2022. [DOI: 10.1016/s0969-8051(22)00073-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
Götz M, Yakushev A, Götz S, Di Nitto A, Düllmann CE, Asai M, Kindler B, Krier J, Lommel B, Nagame Y, Sato TK, Suzuki H, Tomitsuka T, Tokoi K, Toyoshima A, Tsukada K. Application of a novel gas phase synthesis approach to carbonyl complexes of accelerator-produced 5d transition metals. RADIOCHIM ACTA 2021. [DOI: 10.1515/ract-2021-1028] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
In 2014 the first synthesis of a transactinide carbonyl complex – seaborgium hexacarbonyl – was reported. This was achieved in gas-phase chemical experiments in a beam-free environment behind the recoil separator GARIS. Extending this work to heavier elements requires more efficient techniques to synthesize carbonyl complexes as production rates of transactinide elements drop with increasing atomic number. A novel approach was thus conceived, which retains the benefit of a beam-free environment but avoids the physical preseparation step. The latter reduces the yields for products of asymmetric reactions such as those used for the synthesis of suitable isotopes of Sg, Bh, Hs and Mt. For this a series of experiments with accelerator-produced radioisotopes of the lighter homologues W, Re and Os was carried out at the tandem accelerator of JAEA Tokai, Japan. A newly developed double-chamber system, which allows for a decoupled recoil ion thermalization and chemical complex formation, was used, which avoids the low-efficiency physical preseparation step. Here, we demonstrate the feasibility of this newly developed method using accelerator-produced short-lived radioisotopes of the 5d homologues of the early transactinides.
Collapse
Affiliation(s)
- Michael Götz
- Department of Chemistry – TRIGA Site , Johannes Gutenberg University Mainz , 55128 Mainz , Germany
- GSI Helmholtz Centre for Heavy Ion Research , 64291 Darmstadt , Germany
- Helmholtz Institute Mainz , 55099 Mainz , Germany
| | | | - Stefan Götz
- Department of Chemistry – TRIGA Site , Johannes Gutenberg University Mainz , 55128 Mainz , Germany
- GSI Helmholtz Centre for Heavy Ion Research , 64291 Darmstadt , Germany
- Helmholtz Institute Mainz , 55099 Mainz , Germany
| | - Antonio Di Nitto
- Physics Department Ettore Pancini , University of Naples Federico II , 80126 Naples , Italy
| | - Christoph E. Düllmann
- Department of Chemistry – TRIGA Site , Johannes Gutenberg University Mainz , 55128 Mainz , Germany
- GSI Helmholtz Centre for Heavy Ion Research , 64291 Darmstadt , Germany
- Helmholtz Institute Mainz , 55099 Mainz , Germany
| | - Masato Asai
- Japan Atomic Energy Agency , Tokai-mura , Ibaraki 319-1111 , Japan
| | - Birgit Kindler
- GSI Helmholtz Centre for Heavy Ion Research , 64291 Darmstadt , Germany
| | - Jörg Krier
- GSI Helmholtz Centre for Heavy Ion Research , 64291 Darmstadt , Germany
| | - Bettina Lommel
- GSI Helmholtz Centre for Heavy Ion Research , 64291 Darmstadt , Germany
| | - Yuichiro Nagame
- Japan Atomic Energy Agency , Tokai-mura , Ibaraki 319-1111 , Japan
| | - Tetsuya K. Sato
- Japan Atomic Energy Agency , Tokai-mura , Ibaraki 319-1111 , Japan
| | - Hayato Suzuki
- Japan Atomic Energy Agency , Tokai-mura , Ibaraki 319-1111 , Japan
- Ibaraki University , Mito , Ibaraki 310-8512 , Japan
| | | | - Katsuyuki Tokoi
- Japan Atomic Energy Agency , Tokai-mura , Ibaraki 319-1111 , Japan
- Osaka University , Suita , Osaka 565-0871 , Japan
| | - Atsushi Toyoshima
- Japan Atomic Energy Agency , Tokai-mura , Ibaraki 319-1111 , Japan
- Osaka University , Suita , Osaka 565-0871 , Japan
| | - Kazuaki Tsukada
- Japan Atomic Energy Agency , Tokai-mura , Ibaraki 319-1111 , Japan
| |
Collapse
|
18
|
Yakushev A, Lens L, Düllmann CE, Block M, Brand H, Calverley T, Dasgupta M, Di Nitto A, Götz M, Götz S, Haba H, Harkness-Brennan L, Herzberg RD, Heßberger FP, Hinde D, Hübner A, Jäger E, Judson D, Khuyagbaatar J, Kindler B, Komori Y, Konki J, Kratz J, Krier J, Kurz N, Laatiaoui M, Lommel B, Lorenz C, Maiti M, Mistry A, Mokry C, Nagame Y, Papadakis P, Såmark-Roth A, Rudolph D, Runke J, Sarmiento L, Sato T, Schädel M, Scharrer P, Schausten B, Steiner J, Thörle-Pospiech P, Toyoshima A, Trautmann N, Uusitalo J, Ward A, Wegrzecki M, Yakusheva V. First Study on Nihonium (Nh, Element 113) Chemistry at TASCA. Front Chem 2021; 9:753738. [PMID: 34917588 PMCID: PMC8669335 DOI: 10.3389/fchem.2021.753738] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2021] [Accepted: 10/27/2021] [Indexed: 11/13/2022] Open
Abstract
Nihonium (Nh, element 113) and flerovium (Fl, element 114) are the first superheavy elements in which the 7p shell is occupied. High volatility and inertness were predicted for Fl due to the strong relativistic stabilization of the closed 7p 1/2 sub-shell, which originates from a large spin-orbit splitting between the 7p 1/2 and 7p 3/2 orbitals. One unpaired electron in the outermost 7p 1/2 sub-shell in Nh is expected to give rise to a higher chemical reactivity. Theoretical predictions of Nh reactivity are discussed, along with results of the first experimental attempts to study Nh chemistry in the gas phase. The experimental observations verify a higher chemical reactivity of Nh atoms compared to its neighbor Fl and call for the development of advanced setups. First tests of a newly developed detection device miniCOMPACT with highly reactive Fr isotopes assure that effective chemical studies of Nh are within reach.
Collapse
Affiliation(s)
- A. Yakushev
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
| | - L. Lens
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - Ch. E. Düllmann
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - M. Block
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - H. Brand
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - T. Calverley
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - M. Dasgupta
- Department of Nuclear Physics, Australian National University, Canberra, ACT, Australia
| | - A. Di Nitto
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - M. Götz
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - S. Götz
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | | | | | - R-D. Herzberg
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - F. P. Heßberger
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
| | - D. Hinde
- Department of Nuclear Physics, Australian National University, Canberra, ACT, Australia
| | - A. Hübner
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - E. Jäger
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - D. Judson
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - J. Khuyagbaatar
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
| | - B. Kindler
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | | | - J. Konki
- Department of Physics, University of Jyväskylä, Jyväskylä, Finland
| | - J.V. Kratz
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - J. Krier
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - N. Kurz
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - M. Laatiaoui
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
| | - B. Lommel
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | | | - M. Maiti
- Indian Institute of Technology Roorkee, Roorkee, India
| | - A.K. Mistry
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
| | - Ch. Mokry
- Helmholtz-Institut Mainz, Mainz, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - Y. Nagame
- Japan Atomic Energy Agency, Tokai, Japan
| | - P. Papadakis
- Department of Physics, University of Jyväskylä, Jyväskylä, Finland
| | | | - D. Rudolph
- Department of Physics, Lund University, Lund, Sweden
| | - J. Runke
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | | | - T.K. Sato
- Japan Atomic Energy Agency, Tokai, Japan
| | - M. Schädel
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - P. Scharrer
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - B. Schausten
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - J. Steiner
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
| | - P. Thörle-Pospiech
- Helmholtz-Institut Mainz, Mainz, Germany
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | | | - N. Trautmann
- Johannes Gutenberg-Universität Mainz, Mainz, Germany
| | - J. Uusitalo
- Department of Physics, University of Jyväskylä, Jyväskylä, Finland
| | - A. Ward
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - M. Wegrzecki
- Łukasiewicz-Instytut Mikroelektroniki I Fotoniki, Warsaw, Poland
| | - V. Yakusheva
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany
- Helmholtz-Institut Mainz, Mainz, Germany
| |
Collapse
|
19
|
Suzuki H, Kaizuka Y, Tatsuta M, Tanaka H, Washiya N, Shirakami Y, Ooe K, Toyoshima A, Watabe T, Teramoto T, Sasaki I, Watanabe S, Ishioka NS, Hatazawa J, Uehara T, Arano Y. Neopentyl Glycol as a Scaffold to Provide Radiohalogenated Theranostic Pairs of High In Vivo Stability. J Med Chem 2021; 64:15846-15857. [PMID: 34708646 DOI: 10.1021/acs.jmedchem.1c01147] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The high in vivo stability of 2,2-dihydroxymethyl-3-[18F]fluoropropyl-2-nitroimidazole ([18F]DiFA) prompted us to evaluate neopentyl as a scaffold to prepare a radiotheranostic system with radioiodine and astatine. Three DiFA analogues with one, two, or without a hydroxyl group were synthesized. While all 125I-labeled compounds remained stable against nucleophilic substitution, only a 125I-labeled neopentyl glycol was stable against cytochrome P450 (CYP)-mediated metabolism and showed high stability against in vivo deiodination. 211At-labeled neopentyl glycol also remained stable against both nucleophilic substitution and CYP-mediated metabolism. 211At-labeled neopentyl glycol showed the biodistribution profiles similar to those of its radioiodinated counterpart in contrast to the 125I/211At-labeled benzoate pair. The urine analyses confirmed that 211At-labeled neopentyl glycol was excreted in the urine as a glucuronide conjugate with the absence of free [211At]At-. These findings indicate that neopentyl glycol would constitute a promising scaffold to prepare a radiotheranostic system with radioiodine and 211At.
Collapse
Affiliation(s)
- Hiroyuki Suzuki
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan
| | - Yuta Kaizuka
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan
| | - Maho Tatsuta
- Department of Chemical Science and Engineering, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8552, Japan
| | - Hiroshi Tanaka
- Department of Chemical Science and Engineering, Tokyo Institute of Technology, 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8552, Japan
| | - Nana Washiya
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan
| | - Yoshifumi Shirakami
- Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan
| | - Kazuhiro Ooe
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
| | - Atsushi Toyoshima
- Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan
| | - Tadashi Watabe
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
| | - Takahiro Teramoto
- Institute for Radiation Sciences, Osaka University, 1-1 Machikaneyama, Toyonaka, Osaka 560-0043, Japan
| | - Ichiro Sasaki
- Department of Radiation-Applied Biology Research, Takasaki Advanced Radiation Research Institute, National Institutes for Quantum and Radiological Science and Technology, 1233 Watanuki, Takasaki, Gunma 370-1292, Japan
| | - Shigeki Watanabe
- Department of Radiation-Applied Biology Research, Takasaki Advanced Radiation Research Institute, National Institutes for Quantum and Radiological Science and Technology, 1233 Watanuki, Takasaki, Gunma 370-1292, Japan
| | - Noriko S Ishioka
- Department of Radiation-Applied Biology Research, Takasaki Advanced Radiation Research Institute, National Institutes for Quantum and Radiological Science and Technology, 1233 Watanuki, Takasaki, Gunma 370-1292, Japan
| | - Jun Hatazawa
- Research Center for Nuclear Physics, Osaka University, 10-1 Mihogaoka, Ibaraki, Osaka 567-0047, Japan
| | - Tomoya Uehara
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan
| | - Yasushi Arano
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan
| |
Collapse
|
20
|
Shirakami Y, Watabe T, Obata H, Kaneda K, Ooe K, Liu Y, Teramoto T, Toyoshima A, Shinohara A, Shimosegawa E, Hatazawa J, Fukase K. Synthesis of [ 211At]4-astato-L-phenylalanine by dihydroxyboryl-astatine substitution reaction in aqueous solution. Sci Rep 2021; 11:12982. [PMID: 34155314 PMCID: PMC8217504 DOI: 10.1038/s41598-021-92476-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2021] [Accepted: 06/08/2021] [Indexed: 11/08/2022] Open
Abstract
Astatine-211 (211At)-labeled phenylalanine is expected to be a promising agent for targeted alpha-particle therapy for the treatment of patients with glioma. The existing reactions to prepare the labeled compound usually require organic solvents and metals that are toxic and hazardous to the environment. In this study, we developed a novel method wherein astatination was realized via the substitution of 211At for a dihydroxyboryl group coupled to phenylalanine. [211At]4-astato-L-phenylalanine was obtained as the carrier-free product in aqueous medium in high radiochemical yields (98.1 ± 1.9%, n = 5). The crude reaction mixture was purified by solid-phase extraction, and the radiochemical purity of the product was 99.3 ± 0.7% (n = 5). The high yield and purity were attributed to the formation of [211At]AtI and AtI2- as the reactive intermediates in the astatination reaction. The reaction did not require any organic solvents or toxic reagents, suggesting that this method is suitable for clinical applications.
Collapse
Affiliation(s)
- Yoshifumi Shirakami
- Institute for Radiation Sciences, Osaka University, Suita, 565-0871, Japan.
- Research Center for Nuclear Physics, Osaka University, Suita, 565-0871, Japan.
| | - Tadashi Watabe
- Institute for Radiation Sciences, Osaka University, Suita, 565-0871, Japan
- Department of Tracer Kinetics and Nuclear Medicine, Graduate School of Medicine, Osaka University, Suita, 565-0871, Japan
| | - Honoka Obata
- Department of Chemistry, Graduate School of Science, Osaka University, Toyonaka, 560-0043, Japan
| | - Kazuko Kaneda
- Institute for Radiation Sciences, Osaka University, Suita, 565-0871, Japan
| | - Kazuhiro Ooe
- Institute for Radiation Sciences, Osaka University, Suita, 565-0871, Japan
- Department of Tracer Kinetics and Nuclear Medicine, Graduate School of Medicine, Osaka University, Suita, 565-0871, Japan
| | - Yuwei Liu
- Department of Tracer Kinetics and Nuclear Medicine, Graduate School of Medicine, Osaka University, Suita, 565-0871, Japan
| | - Takahiro Teramoto
- Institute for Radiation Sciences, Osaka University, Suita, 565-0871, Japan
| | - Atsushi Toyoshima
- Institute for Radiation Sciences, Osaka University, Suita, 565-0871, Japan
| | - Atsushi Shinohara
- Institute for Radiation Sciences, Osaka University, Suita, 565-0871, Japan
- Department of Tracer Kinetics and Nuclear Medicine, Graduate School of Medicine, Osaka University, Suita, 565-0871, Japan
| | - Eku Shimosegawa
- Department of Molecular Imaging in Medicine, Osaka University Graduate School of Medicine, Suita, 565-0871, Japan
| | - Jun Hatazawa
- Research Center for Nuclear Physics, Osaka University, Suita, 565-0871, Japan
| | - Koichi Fukase
- Institute for Radiation Sciences, Osaka University, Suita, 565-0871, Japan
- Department of Chemistry, Graduate School of Science, Osaka University, Toyonaka, 560-0043, Japan
| |
Collapse
|
21
|
Kaneda-Nakashima K, Zhang Z, Manabe Y, Shimoyama A, Kabayama K, Watabe T, Kanai Y, Ooe K, Toyoshima A, Shirakami Y, Yoshimura T, Fukuda M, Hatazawa J, Nakano T, Fukase K, Shinohara A. α-Emitting cancer therapy using 211 At-AAMT targeting LAT1. Cancer Sci 2021; 112:1132-1140. [PMID: 33277750 PMCID: PMC7935802 DOI: 10.1111/cas.14761] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2020] [Revised: 11/27/2020] [Accepted: 12/01/2020] [Indexed: 12/28/2022] Open
Abstract
α-Methyl-l-tyrosine (AMT) has a high affinity for the cancer-specific l-type amino acid transporter 1 (LAT1). Therefore, we established an anti-cancer therapy, with 211 At-labeled α-methyl-l-tyrosine (211 At-AAMT) as a carrier of 211 At into tumors. 211 At-AAMT had high affinity for LAT1, inhibited tumor cell growth, and induced DNA double-stranded breaks in vitro. We evaluated the accumulation of 211 At-AAMT in vivo and the role of LAT1. Treatment with 0.4 MBq/mouse 211 At-AAMT inhibited tumor growth in the PANC-1 tumor model and 1 MBq/mouse 211 At-AAMT inhibited metastasis in the lung of the B16F10 metastasis model. Our results suggested that 211 At would be useful for anti-cancer therapy and that LAT1 is suitable as a target for radionuclide therapy.
Collapse
Affiliation(s)
- Kazuko Kaneda-Nakashima
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,MS-CORE, PRC, Graduate School of Science, Osaka University, Osaka, Japan
| | - ZiJian Zhang
- MS-CORE, PRC, Graduate School of Science, Osaka University, Osaka, Japan.,Laboratory for Natural Product Chemistry, Department of Chemistry, Graduate School of Science, Osaka University, Osaka, Japan
| | - Yoshiyuki Manabe
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,MS-CORE, PRC, Graduate School of Science, Osaka University, Osaka, Japan.,Laboratory for Natural Product Chemistry, Department of Chemistry, Graduate School of Science, Osaka University, Osaka, Japan
| | - Atsushi Shimoyama
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,MS-CORE, PRC, Graduate School of Science, Osaka University, Osaka, Japan.,Laboratory for Natural Product Chemistry, Department of Chemistry, Graduate School of Science, Osaka University, Osaka, Japan
| | - Kazuya Kabayama
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,MS-CORE, PRC, Graduate School of Science, Osaka University, Osaka, Japan.,Laboratory for Natural Product Chemistry, Department of Chemistry, Graduate School of Science, Osaka University, Osaka, Japan
| | - Tadashi Watabe
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - Yoshikatsu Kanai
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Department of Bio-System Pharmacology, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - Kazuhiro Ooe
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - Atsushi Toyoshima
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,MS-CORE, PRC, Graduate School of Science, Osaka University, Osaka, Japan
| | - Yoshifumi Shirakami
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,MS-CORE, PRC, Graduate School of Science, Osaka University, Osaka, Japan.,Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - Takashi Yoshimura
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Radioisotope Research Center, Institute for Radiation Sciences, Osaka University, Osaka, Japan
| | - Mitsuhiro Fukuda
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Research Center for Nuclear Physics, Osaka University, Osaka, Japan
| | - Jun Hatazawa
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - Takashi Nakano
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Research Center for Nuclear Physics, Osaka University, Osaka, Japan
| | - Koichi Fukase
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,MS-CORE, PRC, Graduate School of Science, Osaka University, Osaka, Japan.,Laboratory for Natural Product Chemistry, Department of Chemistry, Graduate School of Science, Osaka University, Osaka, Japan
| | - Atsushi Shinohara
- Division of Science, Institute for Radiation Sciences, Osaka University, Osaka, Japan.,MS-CORE, PRC, Graduate School of Science, Osaka University, Osaka, Japan.,Laboratory for Radiochemistry, Department of Chemistry, Graduate School of Science, Osaka University, Osaka, Japan
| |
Collapse
|
22
|
Nakanishi K, Yamamoto S, Watabe T, Kaneda‐Nakashima K, Shirakami Y, Ooe K, Toyoshima A, Shinohara A, Teramoto T, Hatazawa J, Kamada K, Yoshikawa A. Development of high‐resolution YAP(Ce) x‐ray camera for the imaging of astatine‐211(At‐211) in small animals. Med Phys 2020; 47:5739-5748. [DOI: 10.1002/mp.14455] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2020] [Revised: 08/02/2020] [Accepted: 08/07/2020] [Indexed: 01/28/2023] Open
Affiliation(s)
- Kouhei Nakanishi
- Department of Integrated Health Science Nagoya University Graduate School of Medicine Nagoya Japan
- Department of Radiology Akita Hospital Chiryu Japan
| | - Seiichi Yamamoto
- Department of Integrated Health Science Nagoya University Graduate School of Medicine Nagoya Japan
| | - Tadashi Watabe
- Department of Nuclear Medicine and Tracer Kinetics Osaka University Graduate School of Medicine Suita Japan
| | | | | | - Kazuhiro Ooe
- Department of Nuclear Medicine and Tracer Kinetics Osaka University Graduate School of Medicine Suita Japan
| | | | - Atsushi Shinohara
- Department of Chemistry Graduate School of Science Osaka University Toyonaka Japan
| | | | - Jun Hatazawa
- Research Center for Nuclear Physics Osaka University Toyonaka Japan
| | - Kei Kamada
- New Industry Creation Hatchery Center (NICHe) Tohoku University Sendai Japan
| | - Akira Yoshikawa
- New Industry Creation Hatchery Center (NICHe) Tohoku University Sendai Japan
| |
Collapse
|
23
|
Ikebe Y, Oshima M, Bamba S, Asai M, Tsukada K, Sato TK, Toyoshima A, Bi C, Seto H, Amano H, Kumada H, Morimoto T. Study of charged particle activation analysis (II): Determination of boron concentration in human blood samples. Appl Radiat Isot 2020; 164:109106. [PMID: 32819495 DOI: 10.1016/j.apradiso.2020.109106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2017] [Revised: 07/05/2019] [Accepted: 02/24/2020] [Indexed: 10/24/2022]
Abstract
Boron Neutron Capture Therapy (BNCT) is a radiotherapy for the treatment of intractable cancer. In BNCT precise determination of 10B concentration in whole blood sample before neutron irradiation of the patient, as well as accurate neutron dosimetry, is crucial for control of the neutron irradiation time. For this purpose ICP-AES and neutron induced prompt γ-ray analysis are generally used. In Ibaraki Neutron Medical Research Center (iNMRC), an intense proton beam will be accelerated up to 8 MeV, which can also be used for Charged Particle Activation Analysis (CPAA). Thus, in this study, we apply the CPAA utilizing the proton beam to non-destructive and accurate determination of 10B concentration in whole blood sample. A CPAA experiment is performed by utilizing an 8 MeV proton beam from the tandem accelerator of Nuclear Science Research Institute in Japan Atomic Energy Agency. The 478 keV γ-ray of 7Be produced by the 10B(p, α)7Be reaction is used to quantify the 10B in human blood. The 478 keV γ-ray intensity is normalized by the intensities of the 847 keV and 1238 keV γ-rays of 56Co originating from Fe in blood. The normalization methods were found to be linear in the range of 3.27 μg 10B/g to 322 μg 10B/g with correlation coefficients of better than 0.9999.
Collapse
Affiliation(s)
- Y Ikebe
- Japan Chemical Analysis Center, Sanno 295-3, Inage, Chiba, 263-0002, Japan.
| | - M Oshima
- Japan Chemical Analysis Center, Sanno 295-3, Inage, Chiba, 263-0002, Japan
| | - S Bamba
- Japan Chemical Analysis Center, Sanno 295-3, Inage, Chiba, 263-0002, Japan
| | - M Asai
- Japan Atomic Energy Agency, Shirakata 2-4, Tokai, Naka, Ibaraki, 319-1195, Japan
| | - K Tsukada
- Japan Atomic Energy Agency, Shirakata 2-4, Tokai, Naka, Ibaraki, 319-1195, Japan
| | - T K Sato
- Japan Atomic Energy Agency, Shirakata 2-4, Tokai, Naka, Ibaraki, 319-1195, Japan
| | - A Toyoshima
- Japan Atomic Energy Agency, Shirakata 2-4, Tokai, Naka, Ibaraki, 319-1195, Japan
| | - C Bi
- Japan Chemical Analysis Center, Sanno 295-3, Inage, Chiba, 263-0002, Japan
| | - H Seto
- Japan Chemical Analysis Center, Sanno 295-3, Inage, Chiba, 263-0002, Japan
| | - H Amano
- Japan Chemical Analysis Center, Sanno 295-3, Inage, Chiba, 263-0002, Japan
| | - H Kumada
- University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki, 305-8575, Japan
| | - T Morimoto
- Japan Chemical Analysis Center, Sanno 295-3, Inage, Chiba, 263-0002, Japan
| |
Collapse
|
24
|
Watabe T, Kaneda-Nakashima K, Shirakami Y, Liu Y, Ooe K, Teramoto T, Toyoshima A, Shimosegawa E, Nakano T, Kanai Y, Shinohara A, Hatazawa J. Targeted alpha therapy using astatine ( 211At)-labeled phenylalanine: A preclinical study in glioma bearing mice. Oncotarget 2020; 11:1388-1398. [PMID: 32341757 PMCID: PMC7170498 DOI: 10.18632/oncotarget.27552] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Accepted: 03/14/2020] [Indexed: 12/13/2022] Open
Abstract
Phenylalanine derivatives, which target tumors especially through L-type amino acid transporter-1 (LAT1), have elicited considerable attention. In this study, we evaluated the treatment effect of phenylalanine labeled with the alpha emitter astatine (211At-PA) in tumor bearing mice. The C6 glioma, U-87MG, and GL261 cell lines were subjected to a cellular 211At-PA uptake analysis that included an evaluation of the uptake inhibition by the system L amino acid transporter inhibitor 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH). BCH significantly inhibited para-211At-PA uptake in C6 glioma (12.2 ± 0.8%), U-87MG (27.6 ± 1.1%), and GL261 (12.6 ± 2.0%) cells compared to baseline, suggesting an uptake contribution by system L amino acid transporters. Subsequently, xenograft and allograft models were prepared by subcutaneously injecting C6 glioma (n = 12) or GL-261 cells (n = 12), respectively. C6 glioma mice received three 211At-PA doses (0.1, 0.5, or 1 MBq, n = 3/dose), while GL261 mice received one high dose (1 MBq, n = 7). 211At-PA exhibited a tumor growth suppression effect in C6 glioma models in a dose-dependent manner as well as in GL-261 models. This phenylalanine derivative labeled with astatine may be applicable as an alpha therapy that specifically targets system L amino acid transporters.
Collapse
Affiliation(s)
- Tadashi Watabe
- Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Suita, Japan.,Institute for Radiation Sciences, Osaka University, Suita, Japan
| | - Kazuko Kaneda-Nakashima
- Institute for Radiation Sciences, Osaka University, Suita, Japan.,Core for Medicine and Science Collaborative Research and Education, Project Research Center for Fundamental Sciences, Graduate School of Science, Osaka University, Toyonaka, Japan
| | | | - Yuwei Liu
- Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Suita, Japan
| | - Kazuhiro Ooe
- Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Suita, Japan.,Institute for Radiation Sciences, Osaka University, Suita, Japan
| | | | | | - Eku Shimosegawa
- Institute for Radiation Sciences, Osaka University, Suita, Japan.,Department of Molecular Imaging in Medicine, Graduate School of Medicine, Osaka University, Suita, Japan
| | - Takashi Nakano
- Institute for Radiation Sciences, Osaka University, Suita, Japan.,Research Center for Nuclear Physics, Osaka University, Ibaraki, Japan
| | - Yoshikatsu Kanai
- Department of Bio-system Pharmacology, Graduate School of Medicine, Osaka University, Suita, Japan
| | - Atsushi Shinohara
- Institute for Radiation Sciences, Osaka University, Suita, Japan.,Department of Chemistry, Graduate School of Science, Osaka University, Toyonaka, Japan
| | - Jun Hatazawa
- Institute for Radiation Sciences, Osaka University, Suita, Japan.,Research Center for Nuclear Physics, Osaka University, Ibaraki, Japan
| |
Collapse
|
25
|
Liu Y, Watabe T, Kaneda-Nakashima K, Ooe K, Shirakami Y, Toyoshima A, Shimosegawa E, Nakano T, Shinohara A, Hatazawa J. Preclinical Evaluation of Radiation-Induced Toxicity in Targeted Alpha Therapy Using [ 211At] NaAt in Mice: A Revisit. Transl Oncol 2020; 13:100757. [PMID: 32220762 PMCID: PMC7109464 DOI: 10.1016/j.tranon.2020.100757] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2020] [Revised: 03/06/2020] [Accepted: 03/08/2020] [Indexed: 11/30/2022] Open
Abstract
We recently reported the dose-dependent therapeutic effect of 211At-NaAt in differentiated thyroid cancer xenograft models. In the present study, we evaluated the radiation-induced toxicity of 211At-NaAt using detailed hematological, biochemical, and histological analyses. Biodistribution of 211At-NaAt was measured in normal ICR mice (n = 12), absorbed doses in the major organs were calculated. Groups of ICR mice (n = 60) were injected with 0.1 MBq or 1 MBq of 211At-NaAt, using saline as the control group (n = 30). Body weight and food intake were followed up for 60 days. Blood cell counts and serum level of biochemical parameters were measured 3, 7, 15, 29, 60 days after injection. Histological analyses of the major organs with hematoxylin and eosin staining were performed. Biodistribution study revealed a high-absorbed dose in the thyroid gland, stomach, bladder, heart, lungs, spleen, kidneys, and testis. The 0.1 MBq group showed no abnormalities. The 1 MBq group showed decreased body weight and food intake. Histological analysis showed atrophy and fibrosis in the thyroid gland, a transient hypospermatogenesis in the testis on day 29 was found in one mouse. Hematological toxicity was mild and transient. The total cholesterol, albumin, and total protein increased with no signs of recovery, which was considered to be caused by hypothyroidism. High-dose administration of 211At-NaAt showed transient toxicity in the white blood cells and testis without severe hematological or renal toxicity, suggesting its tolerable safety as targeted alpha-therapy for differentiated thyroid cancer in the 1 MBq group.
Collapse
Affiliation(s)
- Yuwei Liu
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
| | - Tadashi Watabe
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; Institute for Radiation Sciences, Osaka University, Toyonaka, Osaka, Japan.
| | - Kazuko Kaneda-Nakashima
- Institute for Radiation Sciences, Osaka University, Toyonaka, Osaka, Japan; Core for Medicine and Science Collaborative Research and Education, Project Research Center for Fundamental Sciences, Osaka University Graduate School of Science, Toyonaka, Osaka, Japan
| | - Kazuhiro Ooe
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; Institute for Radiation Sciences, Osaka University, Toyonaka, Osaka, Japan
| | | | - Atsushi Toyoshima
- Institute for Radiation Sciences, Osaka University, Toyonaka, Osaka, Japan
| | - Eku Shimosegawa
- Institute for Radiation Sciences, Osaka University, Toyonaka, Osaka, Japan; Department of Molecular Imaging in Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
| | - Takashi Nakano
- Institute for Radiation Sciences, Osaka University, Toyonaka, Osaka, Japan; Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka, Japan
| | - Atsushi Shinohara
- Institute for Radiation Sciences, Osaka University, Toyonaka, Osaka, Japan; Department of Chemistry, Graduate School of Science, Osaka University, Toyonaka, Osaka, Japan
| | - Jun Hatazawa
- Institute for Radiation Sciences, Osaka University, Toyonaka, Osaka, Japan; Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka, Japan
| |
Collapse
|
26
|
Kabayama K, Kaneda K, Shinohara A, Shirakami Y, Watabe T, Zhang Z, Toyoshima A, Yoshimura T, Manabe Y, Shimoyama A, Fukase K. Activities of the Consortium for Medicine, Chemistry, and Physics at Osaka University. J Med Imaging Radiat Sci 2019. [DOI: 10.1016/j.jmir.2019.11.126] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
27
|
Suzuki H, Tanaka H, Washiya N, Tatsuta M, Sato Y, Kaizuka Y, Watanabe S, Uehara T, Ishioka N, Shirakami Y, Ooe K, Toyoshima A, Watabe T, Hatazawa J, Arano Y. Radiohalogenated Neopentyl Derivatives: A Novel Scaffold for Radioiodinated and astatinated Compounds of High Stability to In Vivo Dehalogenation. J Med Imaging Radiat Sci 2019. [DOI: 10.1016/j.jmir.2019.11.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
28
|
Toyoshima A, Zhang Z, Kanda A, Ikeda T, Ichimura S, Ooe K, Nagata K, Yoshimura T, Shinohara A. Isolation of At-211 by Dry-distillation under Oxidative Conditions for Targeted Alpha Therapy in Osaka University. J Med Imaging Radiat Sci 2019. [DOI: 10.1016/j.jmir.2019.11.036] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
29
|
Watabe T, Liu Y, Kaneda-Nakashima K, Shirakami Y, Lindner T, Ooe K, Toyoshima A, Nagata K, Shimosegawa E, Haberkorn U, Kratochwil C, Shinohara A, Giesel F, Hatazawa J. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models. J Nucl Med 2019; 61:563-569. [PMID: 31586001 DOI: 10.2967/jnumed.119.233122] [Citation(s) in RCA: 157] [Impact Index Per Article: 31.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Fibroblast activation protein (FAP), which promotes tumor growth and progression, is overexpressed in cancer-associated fibroblasts of many human epithelial cancers. Because of its low expression in normal organs, FAP is an excellent target for theranostics. In this study, we used radionuclides with relatively long half-lives, 64Cu (half-life, 12.7 h) and 225Ac (half-life, 10 d), to label FAP inhibitors (FAPIs) in mice with human pancreatic cancer xenografts. Methods: Male nude mice (body weight, 22.5 ± 1.2 g) were subcutaneously injected with human pancreatic cancer cells (PANC-1, n = 12; MIA PaCa-2, n = 8). Tumor xenograft mice were investigated after the intravenous injection of 64Cu-FAPI-04 (7.21 ± 0.46 MBq) by dynamic and delayed PET scans (2.5 h after injection). Static scans 1 h after the injection of 68Ga-FAPI-04 (3.6 ± 1.4 MBq) were also acquired for comparisons using the same cohort of mice (n = 8). Immunohistochemical staining was performed to confirm FAP expression in tumor xenografts using an FAP-α-antibody. For radioligand therapy, 225Ac-FAPI-04 (34 kBq) was injected into PANC-1 xenograft mice (n = 6). Tumor size was monitored and compared with that of control mice (n = 6). Results: Dynamic imaging of 64Cu-FAPI-04 showed rapid clearance through the kidneys and slow washout from tumors. Delayed PET imaging of 64Cu-FAPI-04 showed mild uptake in tumors and relatively high uptake in the liver and intestine. Accumulation levels in the tumor or normal organs were significantly higher for 64Cu-FAPI-04 than for 68Ga-FAPI-04, except in the heart, and excretion in the urine was higher for 68Ga-FAPI-04 than for 64Cu-FAPI-04. Immunohistochemical staining revealed abundant FAP expression in the stroma of xenografts. 225Ac-FAPI-04 injection showed significant tumor growth suppression in the PANC-1 xenograft mice, compared with the control mice, without a significant change in body weight. Conclusion: This proof-of-concept study showed that 64Cu-FAPI-04 and 225Ac-FAPI-04 could be used in theranostics for the treatment of FAP-expressing pancreatic cancer. α-therapy targeting FAP in the cancer stroma is effective and will contribute to the development of a new treatment strategy.
Collapse
Affiliation(s)
- Tadashi Watabe
- Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Osaka, Japan .,Institute for Radiation Sciences, Osaka University, Osaka, Japan
| | - Yuwei Liu
- Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - Kazuko Kaneda-Nakashima
- Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Core for Medicine and Science Collaborative Research and Education, Project Research Center for Fundamental Sciences, Graduate School of Science, Osaka University, Osaka, Japan
| | | | - Thomas Lindner
- Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
| | - Kazuhiro Ooe
- Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Osaka, Japan.,Institute for Radiation Sciences, Osaka University, Osaka, Japan
| | - Atsushi Toyoshima
- Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Core for Medicine and Science Collaborative Research and Education, Project Research Center for Fundamental Sciences, Graduate School of Science, Osaka University, Osaka, Japan
| | - Kojiro Nagata
- Radioisotope Research Center, Institute for Radiation Sciences, Osaka University, Osaka, Japan
| | - Eku Shimosegawa
- Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Department of Molecular Imaging in Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - Uwe Haberkorn
- Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.,Clinical Cooperation Unit of Nuclear Medicine, DKFZ, Heidelberg, Germany.,Translational Lung Research Center Heidelberg, German Center for Lung Research (DZL), Heidelberg, Germany
| | - Clemens Kratochwil
- Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
| | - Atsushi Shinohara
- Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Department of Chemistry, Graduate School of Science, Osaka University, Osaka, Japan; and
| | - Frederik Giesel
- Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
| | - Jun Hatazawa
- Institute for Radiation Sciences, Osaka University, Osaka, Japan.,Research Center for Nuclear Physics, Osaka University, Osaka, Japan
| |
Collapse
|
30
|
Chiera NM, Sato TK, Tomitsuka T, Asai M, Ito Y, Shirai K, Suzuki H, Tokoi K, Toyoshima A, Tsukada K, Nagame Y. Optimization of an isothermal gas-chromatographic setup for the chemical exploration of dubnium (Db, Z = 105) oxychlorides. J Radioanal Nucl Chem 2019. [DOI: 10.1007/s10967-019-06505-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
31
|
Suzuki H, Tanaka H, Washiya N, Tatsuta M, Sato Y, Kaizuka Y, Watanabe S, Uehara T, Ishioka N, Shirakami Y, Ooe K, Toyoshima A, Watabe T, Hatazawa J, Arano Y. Radiohalogenated Neopentyl Derivatives: A Novel Scaffold for Radioiodinated and astatinated Compounds of High Stability to In Vivo Dehalogenation. J Med Imaging Radiat Sci 2019. [DOI: 10.1016/j.jmir.2019.03.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Toyoshima A, Zhang Z, Kanda A, Ikeda T, Ichimura S, Ooe K, Nagata K, Yoshimura T, Shinohara A. Isolation of At-211 by Dry-distillation under Oxidative Conditions for Targeted Alpha Therapy in Osaka University. J Med Imaging Radiat Sci 2019. [DOI: 10.1016/j.jmir.2019.03.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Ooe K, Watabe T, Kaneda-Nakashima K, Liu Y, Shirakami Y, Toyoshima A, Shimosegawa E, Fukuda M, Shinohara A, Hatazawa J. Increased Uptake of At-211 in Thyroid Gland by the Preparation with Ascorbic Acid for Targeted Alpha Therapy of Thyroid Cancer. J Med Imaging Radiat Sci 2019. [DOI: 10.1016/j.jmir.2019.03.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
34
|
Watabe T, Kaneda-Nakashima K, Liu Y, Shirakami Y, Ooe K, Toyoshima A, Shimosegawa E, Fukuda M, Shinohara A, Hatazawa J. Enhancement of 211At Uptake via the Sodium Iodide Symporter by the Addition of Ascorbic Acid in Targeted α-Therapy of Thyroid Cancer. J Nucl Med 2019; 60:1301-1307. [PMID: 30796173 PMCID: PMC6735285 DOI: 10.2967/jnumed.118.222638] [Citation(s) in RCA: 42] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Accepted: 01/29/2019] [Indexed: 12/20/2022] Open
Abstract
211At is an α-emitter that has similar chemical properties to iodine and is used in targeted α-therapy. In the present study, we added ascorbic acid (AA) to 211At solution to increase the radiochemical purity of astatide and evaluated its efficacy against differentiated thyroid cancer, which is characterized by the expression of sodium/iodide symporter (NIS). Methods: Crude 211At solution (AA(-)) and 211At solution treated with AA (AA(+)) were prepared. Uptake by the thyroid was compared between the 2 solutions in normal male Wistar rats (n = 6). Cellular uptake in K1-NIS cells was analyzed under the AA(+) and AA(-) conditions. AA(+) was injected at 3 doses into K1-NIS xenograft mice: 1 MBq (n = 6), 0.4 MBq (n = 6), and 0.1 MBq (n = 6), and vehicle was injected into control mice (n = 6). The treatment effects were compared among the 4 groups. Results: Uptake by the thyroid was significantly enhanced in rats injected with the AA(+) as compared with those injected with AA(-). Cellular uptake analysis showed significantly increased uptake of 211At by the K1-NIS cells under the AA(+) condition as compared with the AA(-) condition. In the mouse xenograft model, the K1-NIS tumors showed significant accumulation of 211At at 3 and 24 h after administration (22.5 ± 10.4 and 12.9 ± 6.8 percentage injected dose, respectively). Tumor growth was immediately inhibited in a dose-dependent manner after administration of 211At. In the survival analysis, the 211At groups (0.1, 0.4, and 1 MBq) showed significantly better survival than the control group. Conclusion: Uptake of 211At was enhanced in differentiated thyroid cancer cells as well as the normal thyroid using 211At solution treated with AA. The method also showed dose-dependent efficacy against the K1-NIS xenografts, suggesting its potential applicability to targeted α-therapy.
Collapse
Affiliation(s)
- Tadashi Watabe
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Kazuko Kaneda-Nakashima
- Core for Medicine and Science Collaborative Research and Education, Project Research Center for Fundamental Sciences, Osaka University Graduate School of Science, Osaka, Japan
| | - Yuwei Liu
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Yoshifumi Shirakami
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Kazuhiro Ooe
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka, Japan
| | | | - Eku Shimosegawa
- Department of Molecular Imaging in Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Mitsuhiro Fukuda
- Research Center for Nuclear Physics, Osaka University, Osaka, Japan; and
| | - Atsushi Shinohara
- Department of Chemistry, Graduate School of Science, Osaka University, Osaka, Japan
| | - Jun Hatazawa
- Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka, Japan
| |
Collapse
|
35
|
Chiera NM, Sato TK, Tomitsuka T, Asai M, Suzuki H, Tokoi K, Toyoshima A, Tsukada K, Nagame Y. Formation and thermochemical properties of oxychlorides of niobium (Nb) and tantalum (Ta): Towards the gas-phase investigation of dubnium (Db) oxychloride. Inorganica Chim Acta 2019. [DOI: 10.1016/j.ica.2018.10.032] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
Sato TK, Asai M, Borschevsky A, Beerwerth R, Kaneya Y, Makii H, Mitsukai A, Nagame Y, Osa A, Toyoshima A, Tsukada K, Sakama M, Takeda S, Ooe K, Sato D, Shigekawa Y, Ichikawa SI, Düllmann CE, Grund J, Renisch D, Kratz JV, Schädel M, Eliav E, Kaldor U, Fritzsche S, Stora T. First Ionization Potentials of Fm, Md, No, and Lr: Verification of Filling-Up of 5f Electrons and Confirmation of the Actinide Series. J Am Chem Soc 2018; 140:14609-14613. [DOI: 10.1021/jacs.8b09068] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Tetsuya K. Sato
- Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki 319-1195, Japan
| | - Masato Asai
- Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki 319-1195, Japan
| | - Anastasia Borschevsky
- The Van Swinderen Institute for Particle Physics and Gravity, University of Groningen, 9700 AB Groningen, The Netherlands
| | - Randolf Beerwerth
- Theoretisch-Physikalisches Institut, Friedrich-Schiller-Universität, 07743 Jena, Germany
- Helmholtz-Institut Jena, 07743 Jena, Germany
| | - Yusuke Kaneya
- Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki 319-1195, Japan
- Graduate School of Science and Engineering, Ibaraki University, Mito, Ibaraki 310-8512, Japan
| | - Hiroyuki Makii
- Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki 319-1195, Japan
| | - Akina Mitsukai
- Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki 319-1195, Japan
- Graduate School of Science and Engineering, Ibaraki University, Mito, Ibaraki 310-8512, Japan
| | - Yuichiro Nagame
- Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki 319-1195, Japan
- Graduate School of Science and Engineering, Ibaraki University, Mito, Ibaraki 310-8512, Japan
| | - Akihiko Osa
- Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki 319-1195, Japan
| | | | - Kazuaki Tsukada
- Japan Atomic Energy Agency (JAEA), Tokai, Ibaraki 319-1195, Japan
| | - Minoru Sakama
- Graduate School of Biomedical Sciences, Tokushima University, Tokushima 770-8503, Japan
| | - Shinsaku Takeda
- Graduate School of Biomedical Sciences, Tokushima University, Tokushima 770-8503, Japan
| | - Kazuhiro Ooe
- Graduate School of Science and Technology, Niigata University, Niigata 910-2181, Japan
| | - Daisuke Sato
- Graduate School of Science and Technology, Niigata University, Niigata 910-2181, Japan
| | - Yudai Shigekawa
- Graduate School of Science, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - Shin-ichi Ichikawa
- Nishina Center for Accelerator-Based Science, RIKEN, Wako, Saitama 351-0198, Japan
| | - Christoph E. Düllmann
- Institut für Kernchemie, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
- Helmholtz-Institut Mainz, 55099 Mainz, Germany
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - Jessica Grund
- Institut für Kernchemie, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
- Helmholtz-Institut Mainz, 55099 Mainz, Germany
| | - Dennis Renisch
- Institut für Kernchemie, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
- Helmholtz-Institut Mainz, 55099 Mainz, Germany
| | - Jens V. Kratz
- Institut für Kernchemie, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - Matthias Schädel
- GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany
| | - Ephraim Eliav
- School of Chemistry, Tel Aviv University, 69978 Tel Aviv, Israel
| | - Uzi Kaldor
- School of Chemistry, Tel Aviv University, 69978 Tel Aviv, Israel
| | - Stephan Fritzsche
- Theoretisch-Physikalisches Institut, Friedrich-Schiller-Universität, 07743 Jena, Germany
- Helmholtz-Institut Jena, 07743 Jena, Germany
| | | |
Collapse
|
37
|
Yokoyama A, Kitayama Y, Fukuda Y, Kikunaga H, Murakami M, Komori Y, Yano S, Haba H, Tsukada K, Toyoshima A. Extraction behavior of rutherfordium as a cationic fluoride complex with a TTA chelate extractant from HF/HNO3 acidic solutions. RADIOCHIM ACTA 2018. [DOI: 10.1515/ract-2018-2949] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
The aim of this study was to identify relevant Rf chemical species by using reversed-phase extraction chromatography with 2-thenoyltrifluoroacetone (TTA) resin as the stationary phase. Because TTA can be used to extract specific metal ions, the distribution ratios of the system enabled determination of the specific complex formation constant of Rf. We performed several experiments on chemical systems with Zr, Hf, No, and Rf, determined their adsorption coefficients, and deduced the K
d values for Rf.
Collapse
Affiliation(s)
- Akihiko Yokoyama
- Institute of Science and Engineering, Kanazawa University , Kanazawa, Ishikawa 920-1192 , Japan
| | - Yuta Kitayama
- Graduate School of Natural Science and Technology, Kanazawa University , Kanazawa, Ishikawa 920-1192 , Japan
| | - Yoshiki Fukuda
- Graduate School of Natural Science and Technology, Kanazawa University , Kanazawa, Ishikawa 920-1192 , Japan
| | - Hidetoshi Kikunaga
- Research Center for Electron Photon Science, Tohoku University , Sendai, Miyagi 982-0826 , Japan
| | - Masashi Murakami
- Nishina Center for Accelerator-Based Science, RIKEN, Wako , Saitama 351-0198 , Japan
| | - Yukiko Komori
- Nishina Center for Accelerator-Based Science, RIKEN, Wako , Saitama 351-0198 , Japan
| | - Shinya Yano
- Nishina Center for Accelerator-Based Science, RIKEN, Wako , Saitama 351-0198 , Japan
| | - Hiromitsu Haba
- Nishina Center for Accelerator-Based Science, RIKEN, Wako , Saitama 351-0198 , Japan
| | - Kazuaki Tsukada
- Advanced Science Research Center, Japan Atomic Energy Agency , Tokai, Ibaraki 319-1195 , Japan
| | - Atsushi Toyoshima
- Advanced Science Research Center, Japan Atomic Energy Agency , Tokai, Ibaraki 319-1195 , Japan
| |
Collapse
|
38
|
Nishio K, Hirose K, Vermeulen M, Makii H, Orlandi R, Tsukada K, Asai M, Toyoshima A, Sato TK, Nagame Y, Chiba S, Aritomo Y, Tanaka S, Ohtsuki T, Tsekhanovich I, Petrache CM, Andreyev A. Study of fission using multi-nucleon transfer reactions. EPJ Web Conf 2018. [DOI: 10.1051/epjconf/201816900013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Multi-nucleon transfer channels of the reactions of 18O+232Th, 18O+238U, 18O+248Cm were used to measure fission-fragment mass distribution for various nuclides and their excitation energy dependence. Predominantly asymmetric fission is observed at low excitation energies for all the studied cases, with an increase of the symmetric fission towards high excitation energies. Experimental data are compared with predictions of the fluctuation-dissipation model, where effects of multi-chance fission (neutron evaporation prior to fission) was introduced. It was shown that a reliable understanding of the observed fission fragment mass distributions can be obtained only invoking multi-chance fissions.
Collapse
|
39
|
Toyoshima A, Osada SI, Umebayashi Y, Manabe M. Mutually exclusive expression pattern of keratin markers for differentiation and proliferation in circumscribed palmar hypokeratosis. Br J Dermatol 2017; 177:e122-e124. [DOI: 10.1111/bjd.15407] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- A. Toyoshima
- Department of Dermatology and Plastic Surgery; Akita University Graduate School of Medicine; Hondo1-1-1 Akita 010-8543 Japan
| | - S.-I. Osada
- Department of Dermatology and Plastic Surgery; Akita University Graduate School of Medicine; Hondo1-1-1 Akita 010-8543 Japan
| | - Y. Umebayashi
- Department of Dermatology and Plastic Surgery; Akita University Graduate School of Medicine; Hondo1-1-1 Akita 010-8543 Japan
| | - M. Manabe
- Department of Dermatology and Plastic Surgery; Akita University Graduate School of Medicine; Hondo1-1-1 Akita 010-8543 Japan
| |
Collapse
|
40
|
Affiliation(s)
| | - S. Sato
- Osaka University, Suita, Osaka, Japan
| |
Collapse
|
41
|
Nishio K, Hirose K, Mark V, Makii H, Orlandi R, Tsukada K, Asai M, Toyoshima A, Sato TK, Nagame Y, Chiba S, Aritomo Y, Tanaka S, Ohtsuki T, Tsekhanovich I, Petrache CM, Andreyev A. Study of fission using multi-nucleon transfer reactions. EPJ Web Conf 2017. [DOI: 10.1051/epjconf/201716300041] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Eichler R, Asai M, Brand H, Chiera N, Di Nitto A, Dressler R, Düllmann C, Even J, Fangli F, Goetz M, Haba H, Hartmann W, Jäger E, Kaji D, Kanaya J, Kaneya Y, Khuyagbaatar J, Kindler B, Komori Y, Kraus B, Kratz J, Krier J, Kudou Y, Kurz N, Miyashita S, Morimoto K, Morita K, Murakami M, Nagame Y, Ooe K, Piguet D, Sato N, Sato T, Steiner J, Steinegger P, Sumita T, Takeyama M, Tanaka K, Tomitsuka T, Toyoshima A, Tsukada K, Türler A, Usoltsev I, Wakabayashi Y, Wang Y, Wiehl N, Wittwer Y, Yakushev A, Yamaki S, Yano S, Yamaki S, Qin Z. Complex chemistry with complex compounds. EPJ Web Conf 2016. [DOI: 10.1051/epjconf/201613107005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
|
44
|
Affiliation(s)
- Yuki Kawashima
- Graduate School of Life Sciences, Tohoku University, 2-1-1
Katahira, Aoba-ku, Sendai 980-8577, Japan
| | - Atsushi Toyoshima
- Graduate School of Life Sciences, Tohoku University, 2-1-1
Katahira, Aoba-ku, Sendai 980-8577, Japan
| | - Haruhiko Fuwa
- Graduate School of Life Sciences, Tohoku University, 2-1-1
Katahira, Aoba-ku, Sendai 980-8577, Japan
| | - Makoto Sasaki
- Graduate School of Life Sciences, Tohoku University, 2-1-1
Katahira, Aoba-ku, Sendai 980-8577, Japan
| |
Collapse
|
45
|
Sato TK, Asai M, Borschevsky A, Stora T, Sato N, Kaneya Y, Tsukada K, Düllmann CE, Eberhardt K, Eliav E, Ichikawa S, Kaldor U, Kratz JV, Miyashita S, Nagame Y, Ooe K, Osa A, Renisch D, Runke J, Schädel M, Thörle-Pospiech P, Toyoshima A, Trautmann N. First ionization potential of the heaviest actinide lawrencium, element 103. EPJ Web Conf 2016. [DOI: 10.1051/epjconf/201613105001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
46
|
Nishinaka I, Yokoyama A, Washiyama K, Maeda E, Watanabe S, Hashimoto K, Ishioka NS, Makii H, Toyoshima A, Yamada N, Amano R. Production and separation of astatine isotopes in the 7Li + natPb reaction. J Radioanal Nucl Chem 2015. [DOI: 10.1007/s10967-015-3975-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
47
|
Hatsukawa Y, Hashimoto K, Tsukada K, Sato T, Asai M, Toyoshima A, Nagai Y, Tanimori T, Sonoda S, Kabuki S, Saji H, Kimura H. Production of 95mTc for Compton camera imaging. J Radioanal Nucl Chem 2015. [DOI: 10.1007/s10967-014-3508-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
48
|
Even J, Yakushev A, Düllmann CE, Haba H, Asai M, Sato TK, Brand H, Di Nitto A, Eichler R, Fan FL, Hartmann W, Huang M, Jäger E, Kaji D, Kanaya J, Kaneya Y, Khuyagbaatar J, Kindler B, Kratz JV, Krier J, Kudou Y, Kurz N, Lommel B, Miyashita S, Morimoto K, Morita K, Murakami M, Nagame Y, Nitsche H, Ooe K, Qin Z, Schädel M, Steiner J, Sumita T, Takeyama M, Tanaka K, Toyoshima A, Tsukada K, Türler A, Usoltsev I, Wakabayashi Y, Wang Y, Wiehl N, Yamaki S. Nuclear chemistry. Synthesis and detection of a seaborgium carbonyl complex. Science 2014; 345:1491-3. [PMID: 25237098 DOI: 10.1126/science.1255720] [Citation(s) in RCA: 72] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Experimental investigations of transactinoide elements provide benchmark results for chemical theory and probe the predictive power of trends in the periodic table. So far, in gas-phase chemical reactions, simple inorganic compounds with the transactinoide in its highest oxidation state have been synthesized. Single-atom production rates, short half-lives, and harsh experimental conditions limited the number of experimentally accessible compounds. We applied a gas-phase carbonylation technique previously tested on short-lived molybdenum (Mo) and tungsten (W) isotopes to the preparation of a carbonyl complex of seaborgium, the 106th element. The volatile seaborgium complex showed the same volatility and reactivity with a silicon dioxide surface as those of the hexacarbonyl complexes of the lighter homologs Mo and W. Comparison of the product's adsorption enthalpy with theoretical predictions and data for the lighter congeners supported a Sg(CO)6 formulation.
Collapse
Affiliation(s)
- J Even
- Helmholtz-Institut Mainz, 55099 Mainz, Germany
| | - A Yakushev
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - Ch E Düllmann
- Helmholtz-Institut Mainz, 55099 Mainz, Germany. GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany. Institut für Kernchemie, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany.
| | - H Haba
- RIKEN, Wako, Saitama 351-0198, Japan
| | - M Asai
- Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - T K Sato
- Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - H Brand
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - A Di Nitto
- Institut für Kernchemie, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - R Eichler
- Department of Chemistry and Biochemistry, University of Bern, 3012 Bern, Switzerland. Paul Scherrer Institute, 5232 Villigen, Switzerland
| | - F L Fan
- Institute of Modern Physics, Chinese Academy of Sciences, 730000 Lanzhou, China
| | - W Hartmann
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - M Huang
- RIKEN, Wako, Saitama 351-0198, Japan
| | - E Jäger
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - D Kaji
- RIKEN, Wako, Saitama 351-0198, Japan
| | - J Kanaya
- RIKEN, Wako, Saitama 351-0198, Japan
| | - Y Kaneya
- Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | | | - B Kindler
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - J V Kratz
- Institut für Kernchemie, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - J Krier
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - Y Kudou
- RIKEN, Wako, Saitama 351-0198, Japan
| | - N Kurz
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - B Lommel
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - S Miyashita
- Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan. Department of Chemistry, Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
| | | | - K Morita
- RIKEN, Wako, Saitama 351-0198, Japan. Department of Physics, Kyushu University, Higashi-Ku, Fukuoka, 812-8581, Japan
| | - M Murakami
- RIKEN, Wako, Saitama 351-0198, Japan. Department of Chemistry, Niigata University, Niigata, Niigata 950-2181, Japan
| | - Y Nagame
- Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - H Nitsche
- Department of Chemistry, University of California, Berkeley, CA 94720-1460, USA. Lawrence Berkeley National Laboratory, Berkeley, CA 94720-8169, USA
| | - K Ooe
- Department of Chemistry, Niigata University, Niigata, Niigata 950-2181, Japan
| | - Z Qin
- Institute of Modern Physics, Chinese Academy of Sciences, 730000 Lanzhou, China
| | - M Schädel
- Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - J Steiner
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany
| | - T Sumita
- RIKEN, Wako, Saitama 351-0198, Japan
| | | | - K Tanaka
- RIKEN, Wako, Saitama 351-0198, Japan
| | - A Toyoshima
- Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - K Tsukada
- Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - A Türler
- Department of Chemistry and Biochemistry, University of Bern, 3012 Bern, Switzerland. Paul Scherrer Institute, 5232 Villigen, Switzerland
| | - I Usoltsev
- Department of Chemistry and Biochemistry, University of Bern, 3012 Bern, Switzerland. Paul Scherrer Institute, 5232 Villigen, Switzerland
| | | | - Y Wang
- Institute of Modern Physics, Chinese Academy of Sciences, 730000 Lanzhou, China
| | - N Wiehl
- Helmholtz-Institut Mainz, 55099 Mainz, Germany. Institut für Kernchemie, Johannes Gutenberg-Universität Mainz, 55099 Mainz, Germany
| | - S Yamaki
- RIKEN, Wako, Saitama 351-0198, Japan. Department of Physics, Saitama University, Saitama 338-8570, Japan
| |
Collapse
|
49
|
Toyoshima A, Li Z, Asai M, Sato N, Sato TK, Kikuchi T, Kaneya Y, Kitatsuji Y, Tsukada K, Nagame Y, Schädel M, Ooe K, Kasamatsu Y, Shinohara A, Haba H, Even J. Measurement of the Md3+/Md2+ reduction potential studied with flow electrolytic chromatography. Inorg Chem 2013; 52:12311-3. [PMID: 24116851 DOI: 10.1021/ic401571h] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The reduction behavior of mendelevium (Md) was studied using a flow electrolytic chromatography apparatus. By application of the appropriate potentials on the chromatography column, the more stable Md(3+) is reduced to Md(2+). The reduction potential of the Md(3+) + e(-) → Md(2+) couple was determined to be -0.16 ± 0.05 V versus a normal hydrogen electrode.
Collapse
|
50
|
Miyamoto S, Endo T, Akai R, Toyoshima A, Tatsuta S, Yanagihara Y. Gastrointestinal Perforation by Bevacizumab. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt460.74] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|